PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 25800444-5 2015 To explore the effect of ERK1/2 pathway on AQP4 expression in scratch-injured astrocytes, 10 micromol/L U0126 (ERK1/2 inhibitor) was incubated in the medium at 30 min before the scratch-injury in some groups. U 0126 104-109 mitogen activated protein kinase 3 Rattus norvegicus 25-31 26019344-10 2015 Infusion of RU486 or the Erk1/2 inhibitor U0126, but not propranolol or the PKA inhibitor Rp-cAMPS, into the CA1 before extinction disrupted the formation of extinction LTM, suggesting that hippocampal GR and Erk1/2 but not betaAR or PKA play critical roles in this process. U 0126 42-47 mitogen activated protein kinase 3 Rattus norvegicus 25-31 26109504-10 2015 Importantly, the ERK1/2 inhibitor U0126 reduced the upregulation of fibroblast growth factor-2 and fibrosis biomarkers in angiotensin II-treated fibroblasts. U 0126 34-39 mitogen activated protein kinase 3 Rattus norvegicus 17-23 25999956-8 2015 Moreover, both MEK1/2 and ERK1/2 expression increased significantly, and cellular hypertrophy was markedly attenuated by U0126, an ERK1/2 inhibitor. U 0126 121-126 mitogen activated protein kinase 3 Rattus norvegicus 26-32 25999956-8 2015 Moreover, both MEK1/2 and ERK1/2 expression increased significantly, and cellular hypertrophy was markedly attenuated by U0126, an ERK1/2 inhibitor. U 0126 121-126 mitogen activated protein kinase 3 Rattus norvegicus 131-137 25800444-5 2015 To explore the effect of ERK1/2 pathway on AQP4 expression in scratch-injured astrocytes, 10 micromol/L U0126 (ERK1/2 inhibitor) was incubated in the medium at 30 min before the scratch-injury in some groups. U 0126 104-109 mitogen activated protein kinase 3 Rattus norvegicus 111-117 25800444-8 2015 Furthermore, pretreatment with U0126 blocked both ERK1/2 activation and decrease in AQP4 expression induced by scratch-injury. U 0126 31-36 mitogen activated protein kinase 3 Rattus norvegicus 50-56 25492115-8 2015 In vitro organ culture and tMCAO resulted in vascular ETB receptor upregulation and activation of ERK1/2 that was prevented by U0126. U 0126 127-132 mitogen activated protein kinase 3 Rattus norvegicus 98-104 25042242-7 2014 This effect was abolished by both U0126 (inhibitor of ERK1/2) and also by L-NAME. U 0126 34-39 mitogen activated protein kinase 3 Rattus norvegicus 54-60 25580562-12 2015 Moreover, inhibition of ERK1/2 with U0126 attenuated the BHBA-mediated reduction in Gsh-1 expression and GHRH synthesis and secretion. U 0126 36-41 mitogen activated protein kinase 3 Rattus norvegicus 24-30 25363751-1 2015 U0126 has been reported as a specific inhibitor of the ERK1/2 signaling pathway, which plays a vital role during the osteogenic differentiation of mesenchymal stem cells (MSCs). U 0126 0-5 mitogen activated protein kinase 3 Rattus norvegicus 55-61 25363751-4 2015 Our data indicate that U0126 enhances the BMP/Smad signaling pathway in rat MSCs, while inhibiting the ERK1/2 signaling pathway. U 0126 23-28 mitogen activated protein kinase 3 Rattus norvegicus 103-109 24820887-11 2015 The ERK1/2 antagonist U0126, p38 antagonist SB203580 and JNK antagonist SP600125 significantly reversed the facial mechanical allodynia in ION-CCI rats. U 0126 22-27 mitogen activated protein kinase 3 Rattus norvegicus 4-10 24820887-12 2015 However, the ERK1/2 antagonist U0126, p38 antagonist SB203580 but not JNK antagonist SP600125 significantly increased BKCa currents in ION-CCI TG neurons. U 0126 31-36 mitogen activated protein kinase 3 Rattus norvegicus 13-19 25451564-5 2014 Both I3O and U0126, an extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor, markedly reduced collagen-induced phosphorylation of ERK1/2 and p47, resulting in the blockade of cyclooxygenase (COX)-mediated AA metabolite production in AA-treated platelets. U 0126 13-18 mitogen activated protein kinase 3 Rattus norvegicus 23-64 25451564-5 2014 Both I3O and U0126, an extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor, markedly reduced collagen-induced phosphorylation of ERK1/2 and p47, resulting in the blockade of cyclooxygenase (COX)-mediated AA metabolite production in AA-treated platelets. U 0126 13-18 mitogen activated protein kinase 3 Rattus norvegicus 66-72 25451564-5 2014 Both I3O and U0126, an extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor, markedly reduced collagen-induced phosphorylation of ERK1/2 and p47, resulting in the blockade of cyclooxygenase (COX)-mediated AA metabolite production in AA-treated platelets. U 0126 13-18 mitogen activated protein kinase 3 Rattus norvegicus 138-144 25128810-6 2014 The effects of hispidin on Akt and ERK phosphorylation were abrogated by LY294002 (a PI3K/Akt inhibitor) and U0126 (an ERK1/2 inhibitor). U 0126 109-114 mitogen activated protein kinase 3 Rattus norvegicus 119-125 25352744-5 2014 ERK1/2 activity was inhibited by intravitreal injection of U0126, a highly selective inhibitor of mitogen-activated protein kinase 1/2 (MEK1/2). U 0126 59-64 mitogen activated protein kinase 3 Rattus norvegicus 0-6 26184424-7 2015 Testosterone content was significantly decreased in the DHEA-treated group pre-incubated with U0126 (p-ERK1/2 inhibitor). U 0126 94-99 mitogen activated protein kinase 3 Rattus norvegicus 103-109 26184424-8 2015 Additionally, the rise in p-ERK1/2, 3beta-HSD and 17beta-HSD protein levels induced by DHEA was reversed when cells were pre-incubated with U0126. U 0126 140-145 mitogen activated protein kinase 3 Rattus norvegicus 28-34 25788387-6 2015 One hour prior to adenoviral injections, rats were intraperitoneally administrated with 10 mg/kg U0126 (a specific MEK/ERK1/2 inhibitor) or DMSO (vehicle control). U 0126 97-102 mitogen activated protein kinase 3 Rattus norvegicus 119-125 25503106-7 2014 Additionally, AICAR increased ERK1/2 phosphorylation, and inhibition of ERK1/2 by U0126, an ERK1/2 kinase inhibitor, or by siRNA decreased AICAR-induced TER responses. U 0126 82-87 mitogen activated protein kinase 3 Rattus norvegicus 72-78 25503106-7 2014 Additionally, AICAR increased ERK1/2 phosphorylation, and inhibition of ERK1/2 by U0126, an ERK1/2 kinase inhibitor, or by siRNA decreased AICAR-induced TER responses. U 0126 82-87 mitogen activated protein kinase 3 Rattus norvegicus 72-78 23635511-10 2014 ERK phosphorylation inhibitor U0126 completely reversed the protective effects of melatonin, suggesting that melatonin improves MSC survival and function through activating the ERK1/2 signaling pathway. U 0126 30-35 mitogen activated protein kinase 3 Rattus norvegicus 177-183 24679950-7 2014 The PKMzeta peptide blocker ZIP and MEK inhibitor U0126 significantly inhibited the increase in extracellular signal-regulated kinase 1/2 and cyclic adenosine monophosphate response element binding protein phosphorylation in the mitogen-activated protein kinase (MAPK) pathway and hippocampal NSC neurogenesis in response to fluoxetine and the 5-HT1A receptor agonist 8-OH DPAT. U 0126 50-55 mitogen activated protein kinase 3 Rattus norvegicus 96-137 24679950-7 2014 The PKMzeta peptide blocker ZIP and MEK inhibitor U0126 significantly inhibited the increase in extracellular signal-regulated kinase 1/2 and cyclic adenosine monophosphate response element binding protein phosphorylation in the mitogen-activated protein kinase (MAPK) pathway and hippocampal NSC neurogenesis in response to fluoxetine and the 5-HT1A receptor agonist 8-OH DPAT. U 0126 50-55 mitogen activated protein kinase 3 Rattus norvegicus 263-267 24088960-8 2014 FGF23-induced ERK1/2 phosphorylation was inhibited by SU5402 (FGFR1 inhibitor) and U0126 (MEK inhibitor). U 0126 83-88 mitogen activated protein kinase 3 Rattus norvegicus 14-20 24573389-6 2014 Inhibition of ERK1/2 signaling via U0126 markedly blocked UA-induced MC proliferation. U 0126 35-40 mitogen activated protein kinase 3 Rattus norvegicus 14-20 24866134-8 2014 Pretreatment with U0126, an inhibitor of extracellular signal-regulated kinases 1/2 phosphorylation, abolished the inhibition of elastin gene transcription by A23187. U 0126 18-23 mitogen activated protein kinase 3 Rattus norvegicus 41-83 24811302-7 2014 AOF-stimulated ERK1/2, JNK, and p38 phosphorylation attenuated by individual pretreatment with siRNAs or inhibitors (U0126, SP600125 and SB203580), resulting in migration and uPA-related signal pathway inhibition. U 0126 117-122 mitogen activated protein kinase 3 Rattus norvegicus 15-21 25324681-13 2014 Meanwhile, COX-2, PGE2, and VEGF expression was inhibited by ERK1/2 inhibitor U0126 and COX-2 inhibitor NS-398. U 0126 78-83 mitogen activated protein kinase 3 Rattus norvegicus 61-67 24515297-6 2014 Phosphorylation of ERK1/2 and p38 MAPKs by ORA was blocked with U0126 and SB203580 inhibitors, respectively. U 0126 64-69 mitogen activated protein kinase 3 Rattus norvegicus 19-25 25206883-3 2014 In this study, transient whole-brain ischemia was induced by four-vessel occlusion in normal and diabetic rats, and extracellular signal-regulated kinase 1/2 inhibitor (U0126) was administered into diabetic rats 30 minutes before ischemia as a pretreatment. U 0126 169-174 mitogen activated protein kinase 3 Rattus norvegicus 116-157 25206883-4 2014 Results showed that the number of surviving neurons in the hippocampal CA1 region was reduced, extracellular signal-regulated kinase 1/2 phosphorylation and Ku70 activity were decreased, and pro-apoptotic Bax expression was upregulated after intervention using U0126. U 0126 261-266 mitogen activated protein kinase 3 Rattus norvegicus 95-134 23959527-8 2014 Moreover, addition of the Erk1/2 inhibitor U0126 partially blocked Smad7-siRNA-induced CS closure. U 0126 43-48 mitogen activated protein kinase 3 Rattus norvegicus 26-32 24768830-4 2014 Isoprenaline beta-AR mediated vasodilation of aortic rings was potentiated by the ERK1/2 inhibitor, U0126, in the presence or absence of endothelium or L-NAME, whereas inhibition of p38 had no impact. U 0126 100-105 mitogen activated protein kinase 3 Rattus norvegicus 82-88 24512724-8 2014 Administration of the ERK1/2 inhibitor U0126 decreased the infarct ratio and improved protein clearance by autophagy in the HBO group. U 0126 39-44 mitogen activated protein kinase 3 Rattus norvegicus 22-28 24118820-7 2014 These injuries were significantly attenuated by the pre-treatment of cells with either naringin or SB203580 (a selective inhibitor of p38 MAPK) or U0126 (a selective inhibitor of extracellular signal regulated kinase 1/2, ERK1/2) or SP600125 (a selective inhibitor of c-jun N-termanal kinase, JNK) before exposure to HG, respectively. U 0126 147-152 mitogen activated protein kinase 3 Rattus norvegicus 179-220 24118820-7 2014 These injuries were significantly attenuated by the pre-treatment of cells with either naringin or SB203580 (a selective inhibitor of p38 MAPK) or U0126 (a selective inhibitor of extracellular signal regulated kinase 1/2, ERK1/2) or SP600125 (a selective inhibitor of c-jun N-termanal kinase, JNK) before exposure to HG, respectively. U 0126 147-152 mitogen activated protein kinase 3 Rattus norvegicus 222-228 24357338-6 2014 Furthermore, SB203580 (an inhibitor of p38) decreased the percentage of apoptotic cells whereas arsenite-stimulated toxicity was enhanced by U0126 (an inhibitor of ERK1/2). U 0126 141-146 mitogen activated protein kinase 3 Rattus norvegicus 164-170 24321199-6 2014 These ameliorating effects of orexin-A on spatial learning and memory were attenuated by the intracerebroventricular injection of the OX1R antagonist SB334867 or the ERK1/2 inhibitor U0126. U 0126 183-188 mitogen activated protein kinase 3 Rattus norvegicus 166-172 24440742-13 2014 Inhibition of phosphoinositide-3-kinase (PI3K) by wortmannin and ERK1/2 by U0126 reduced Ft1-evoked relaxations and eNOS phosphorylation. U 0126 75-80 mitogen activated protein kinase 3 Rattus norvegicus 65-71 24071787-5 2014 Inactivation of the epidermal growth factor receptor (EGFR) kinase activity with AG1478 and the mitogen-regulated kinase activity with U0126 completely prevented ERK1/2 activation in the FSH-stimulated and HBCDD-exposed granulosa cells. U 0126 135-140 mitogen activated protein kinase 3 Rattus norvegicus 162-168 24220799-8 2014 Administration of 2-CL-IB-MECA at reperfusion significantly upregulated the status of p-ERK1/2 and p-AKT compared to time matched controls in a UO126 and Wortmannin sensitive manner respectively. U 0126 144-149 mitogen activated protein kinase 3 Rattus norvegicus 88-94 24315856-6 2014 Blockage of ERK1/2 and p38 MAPK signal pathways using MEK1/2 inhibitors (PD98059 and U0126) or p38 inhibitors (SB203580 and SB239063) significantly abolished the LDL-induced upregulation of vasoconstrictive ET(B) receptor expression. U 0126 85-90 mitogen activated protein kinase 3 Rattus norvegicus 12-18 24877090-6 2014 The MAPK inhibitor U0126 blocked ERK1/2 activation and reduced Schwann cell proliferation as well as induction of c-Jun transcription. U 0126 19-24 mitogen activated protein kinase 3 Rattus norvegicus 4-8 24877090-6 2014 The MAPK inhibitor U0126 blocked ERK1/2 activation and reduced Schwann cell proliferation as well as induction of c-Jun transcription. U 0126 19-24 mitogen activated protein kinase 3 Rattus norvegicus 33-39 24358311-8 2013 Pharmacological blockade of MAPK/ERK pathway using U0126, abolished PIMT/Med1-dependent gluconeogenic program leading to reduced hepatic glucose output. U 0126 51-56 mitogen activated protein kinase 3 Rattus norvegicus 28-32 24358311-8 2013 Pharmacological blockade of MAPK/ERK pathway using U0126, abolished PIMT/Med1-dependent gluconeogenic program leading to reduced hepatic glucose output. U 0126 51-56 mitogen activated protein kinase 3 Rattus norvegicus 33-36 23952963-7 2013 This effect could be suppressed by co-treatment with the ERK1/2 inhibitor U0126. U 0126 74-79 mitogen activated protein kinase 3 Rattus norvegicus 57-63 24055892-6 2013 BadSer155 phosphorylation by 6-OHDA was inhibited by PKA (H89) and MEK (U0126) inhibitors, indicating that it was mediated via the cAMP-PKA-sustained ERK1/2 system. U 0126 72-77 mitogen activated protein kinase 3 Rattus norvegicus 150-156 23912965-6 2013 Importantly, pre-treatment of the cells with 400 microM NaHS or 3 microM SB203580 (a selective inhibitor of p38 MAPK) or 15 microM U0126 (a selective inhibitor of ERK1/2) attenuated the HG-induced cardiomyocyte injury, leading to an increase in cell viability and a decrease in the number of apoptotic cells, preventing ROS generation, as well as the loss of MMP. U 0126 131-136 mitogen activated protein kinase 3 Rattus norvegicus 163-169 24044038-3 2013 This response was significantly attenuated by over 60% when ERK1/2 was inhibited by U0126 (7 mug) (P < 0.05). U 0126 84-89 mitogen activated protein kinase 3 Rattus norvegicus 60-66 24049436-9 2013 Interestingly, pretreatment of RGCs with AG1024 (an IGF-1 inhibitor), U0126 (an Erk-1/2 inhibitor), and LY294002 (an Akt inhibitor) markedly attenuated the effects of IGF-1 treatment. U 0126 70-75 mitogen activated protein kinase 3 Rattus norvegicus 80-87 23583632-6 2013 To dissect the signaling cascade involved in atrazine action in granulosa cells, we used U0126, a pharmacological inhibitor of ERK1/2. U 0126 89-94 mitogen activated protein kinase 3 Rattus norvegicus 127-133 23756732-3 2013 Rats were further treated with U0126 (an ERK1/2 phosphorylation inhibitor) 30 min before RA treatment to assess the effects of RA and ERK1/2 signaling in depressive-like behavior and hippocampal BDNF levels. U 0126 31-36 mitogen activated protein kinase 3 Rattus norvegicus 41-47 23519519-7 2013 However, the administration of U0126, a MEK kinase inhibitor, partly blocked MEK1/2 and ERK1/2 phosphorylation induced by tGCI. U 0126 31-36 mitogen activated protein kinase 3 Rattus norvegicus 88-94 23610132-9 2013 Furthermore, the ERK1/2 inhibitor U0126 reversed the inhibitory effect of E2 on alpha,beta-me-ATP-induced pain and of PPT or G-1 on P2X3 receptor-mediated currents. U 0126 34-39 mitogen activated protein kinase 3 Rattus norvegicus 17-23 23772748-6 2013 U0126, which blocked the ERK1/2 pathway, exerted an additive effect on the icariin suppression of type IV collagen and fibronectin expression, enhancing the beneficial effects of icariin. U 0126 0-5 mitogen activated protein kinase 3 Rattus norvegicus 25-31 23242737-7 2013 The functions of trigeminal ganglionic Nav 1.7 and extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation were blocked with the microinjection of the Nav 1.7 antibody or U0126 into the trigeminal ganglion. U 0126 182-187 mitogen activated protein kinase 3 Rattus norvegicus 51-92 23242737-7 2013 The functions of trigeminal ganglionic Nav 1.7 and extracellular signal-regulated kinase 1/2 (ERK1/2) phosphorylation were blocked with the microinjection of the Nav 1.7 antibody or U0126 into the trigeminal ganglion. U 0126 182-187 mitogen activated protein kinase 3 Rattus norvegicus 94-100 23518641-8 2013 Further, EPO activates the PI3K and ERK1/2 pathways in cultured hippocampal neurons, and the PI3K/Akt inhibitor LY294002 and ERK1/2 inhibitor U0126 both blocked, at least in part, the suppressive effect of exogenous EPO on KA-induced calcium currents. U 0126 142-147 mitogen activated protein kinase 3 Rattus norvegicus 125-131 23538210-6 2013 Furthermore, CRH stimulated p53 mRNA via the ERK 1/2 pathway in the BRL-3A cell line and this was blocked by the ERK 1/2 antagonist U0126. U 0126 132-137 mitogen activated protein kinase 3 Rattus norvegicus 45-52 23538210-6 2013 Furthermore, CRH stimulated p53 mRNA via the ERK 1/2 pathway in the BRL-3A cell line and this was blocked by the ERK 1/2 antagonist U0126. U 0126 132-137 mitogen activated protein kinase 3 Rattus norvegicus 113-120 23219579-10 2013 The increasing expressions of p-Akt and p-ERK1/2 induced by Dex in the ischemic hemisphere were markedly inhibited by LY294002 (or wortmannin) and U0126 (or PD98059), respectively. U 0126 147-152 mitogen activated protein kinase 3 Rattus norvegicus 42-48 23232446-4 2013 We show that the mitogen-activated protein kinase (MEK)/ERK1/2 inhibitor, U0126 (1.0 mug/0.5 mul/hemisphere), microinfused bilaterally into the BLA--but not the NACc--immediately after brief re-exposure to a previously cocaine-paired context (that is, cocaine-memory reactivation), significantly attenuated subsequent drug context-induced cocaine seeking relative to vehicle (VEH). U 0126 74-79 mitogen activated protein kinase 3 Rattus norvegicus 56-62 23338747-10 2013 Consistent with these results, palmitate-induced apoptosis was attenuated by the ERK1/2 inhibitor, U0126, through partial reduction of intracellular ROS generation. U 0126 111-116 mitogen activated protein kinase 3 Rattus norvegicus 93-99 23428580-8 2013 Pretreatment with the MAPK/ERK kinase inhibitor U0126 attenuated NMB-induced cell proliferation and DNA synthesis. U 0126 48-53 mitogen activated protein kinase 3 Rattus norvegicus 22-26 23428580-8 2013 Pretreatment with the MAPK/ERK kinase inhibitor U0126 attenuated NMB-induced cell proliferation and DNA synthesis. U 0126 48-53 mitogen activated protein kinase 3 Rattus norvegicus 27-30 23481295-10 2013 U0126, a specific inhibitor of mitogen activated protein kinases kinase, blocked ghrelin- and des-acyl ghrelin-induced ERK1/2 phosphorylation and cell proliferation in IEC-6 cells. U 0126 0-5 mitogen activated protein kinase 3 Rattus norvegicus 119-125 23291919-7 2013 Furthermore, the proliferative effect and promotion of NSCs differentiating predominantly into neurons of paroxetine was inhibited by U0126, an ERK1/2 phosphorylation inhibitor. U 0126 134-139 mitogen activated protein kinase 3 Rattus norvegicus 144-150 23374450-11 2013 ERK1/2 inhibitor U0126 attenuated the increase of proliferation and cyclin D1 induced by VU0155041. U 0126 17-22 mitogen activated protein kinase 3 Rattus norvegicus 0-6 23671886-0 2013 The ERK1/2 Inhibitor U0126 Attenuates Diabetes-Induced Upregulation of MMP-9 and Biomarkers of Inflammation in the Retina. U 0126 21-26 mitogen activated protein kinase 3 Rattus norvegicus 4-10 23223107-15 2013 Either EA at acupoints or intrathecal injection of U0126 relieved allodynia and hyperalgesia and reduced the expression of P2X3 receptors and ERK1/2 phosphorylation in the spinal cord. U 0126 51-56 mitogen activated protein kinase 3 Rattus norvegicus 142-148 23200898-7 2013 Western blot analysis also showed that Danshensu increased phosphorylation of Akt and extracellular signal-related kinase 1/2 (ERK1/2) in H9c2 cells, and the protective effects of Danshensu were partially inhibited by phosphatidylinositol 3"-kinase (PI3K) specific inhibitor wortmannin or ERK specific inhibitor U0126. U 0126 312-317 mitogen activated protein kinase 3 Rattus norvegicus 127-133 23318214-6 2013 Furthermore, U0126 strongly inhibited PEMF-dependent ERK1/2 activation and neuritogenesis. U 0126 13-18 mitogen activated protein kinase 3 Rattus norvegicus 53-59 23671886-5 2013 Intravitreal administration of the ERK1/2 inhibitor U0126 prior to induction of diabetes decreased ERK1/2 activation, attenuated diabetes-induced upregulation of MMP-9, iNOS, IL-6, and TNF- alpha and upregulated TIMP-1 expression. U 0126 52-57 mitogen activated protein kinase 3 Rattus norvegicus 35-41 23671886-5 2013 Intravitreal administration of the ERK1/2 inhibitor U0126 prior to induction of diabetes decreased ERK1/2 activation, attenuated diabetes-induced upregulation of MMP-9, iNOS, IL-6, and TNF- alpha and upregulated TIMP-1 expression. U 0126 52-57 mitogen activated protein kinase 3 Rattus norvegicus 99-105 22452662-8 2013 In vitro, heat stress caused damage and apoptosis in IEC-6 cells; inhibition of ERK1/2 activation (by U0126) exacerbated these effects, which were attenuated by inhibition of JNK (by SP600125) and p38 (by SB203580) activation. U 0126 102-107 mitogen activated protein kinase 3 Rattus norvegicus 80-86 23259581-16 2012 Inhibition of the MEK-ERK1/2 pathway by U0126 starting at 6 h post-SAH prevented upregulation of cytokines and MMP-9 in cerebral vessels, and improved neurological outcome. U 0126 40-45 mitogen activated protein kinase 3 Rattus norvegicus 22-28 23259581-4 2012 Secondly, we investigated whether administration of a specific mitogen-activated protein kinase kinase (MEK)1/2 inhibitor, U0126, given at 6 h after SAH prevents activation of the MEK/extracellular signal-regulated kinase 1/2 pathway and the upregulation of cerebrovascular inflammatory mediators and improves neurological function. U 0126 123-128 mitogen activated protein kinase 3 Rattus norvegicus 184-223 23259581-12 2012 Treatment with U0126 starting at 6 h after SAH prevented activation of MEK-ERK1/2 signaling. U 0126 15-20 mitogen activated protein kinase 3 Rattus norvegicus 75-81 23028124-4 2012 Also, ouabain upregulated the expression of cyclin D1 and incorporation of [methyl-(3)H]thymidine, both of which were dependent on MAPK3/1 but not AKT intracellular cascade, as shown by pretreatment with MEK (MAP2K1/2) inhibitor U0126 and PI3K inhibitor wortmannin respectively. U 0126 229-234 mitogen activated protein kinase 3 Rattus norvegicus 131-138 22878563-9 2012 However, when ERK1/2 phosphorylation was specifically inhibited by U0126, the increase in DJ-1 expression occurring during HP was almost completely abolished and, as a result, the delayed cardioprotection induced by HP was abolished, and the inhibitory effect of HP on H/R-induced oxidant stress was also reversed. U 0126 67-72 mitogen activated protein kinase 3 Rattus norvegicus 14-20 23050488-10 2012 In line with these results, the protective effect of adiponectin can be blocked by PI3K/Akt inhibitor LY294002, and palmitate-induced apoptosis can be attenuated by ERK1/2 inhibitor U0126. U 0126 182-187 mitogen activated protein kinase 3 Rattus norvegicus 165-171 22581061-8 2012 Stretch-mediated I-Smad mRNAs of cells pre-treated with MAPK-ERK kinase inhibitor, U0126, were also determined. U 0126 83-88 mitogen activated protein kinase 3 Rattus norvegicus 61-64 22534050-7 2012 ERK1/2 phosphorylation inhibitor U0126 can block downstream iNOS expression and NO generation. U 0126 33-38 mitogen activated protein kinase 3 Rattus norvegicus 0-6 22580375-10 2012 Finally, pharmacological experiments showed that administration of inhibitors of either MAPK/ERK (U0126) or PI3K (LY294002) blocked VEGF-stimulation of hippocampal cell proliferation in vivo and in vitro. U 0126 98-103 mitogen activated protein kinase 3 Rattus norvegicus 88-92 22609091-6 2012 Inhibition of the PI3K/Akt and ERK1/2 pathways by specific inhibitors, LY294002 and U0126, respectively, partially reduce the protective effect of bFGF. U 0126 84-89 mitogen activated protein kinase 3 Rattus norvegicus 31-37 22957439-5 2012 Phosphorylation of ERK1/2 at Thr-202/Tyr-204 and Raf-1 at Ser-338 were inhibited by the Raf-1 inhibitor GW5074, while the ERK1/2 pathway inhibitor U0126 decreased phosphorylation of ERK1/2. U 0126 147-152 mitogen activated protein kinase 3 Rattus norvegicus 19-25 22957439-5 2012 Phosphorylation of ERK1/2 at Thr-202/Tyr-204 and Raf-1 at Ser-338 were inhibited by the Raf-1 inhibitor GW5074, while the ERK1/2 pathway inhibitor U0126 decreased phosphorylation of ERK1/2. U 0126 147-152 mitogen activated protein kinase 3 Rattus norvegicus 122-128 22957439-5 2012 Phosphorylation of ERK1/2 at Thr-202/Tyr-204 and Raf-1 at Ser-338 were inhibited by the Raf-1 inhibitor GW5074, while the ERK1/2 pathway inhibitor U0126 decreased phosphorylation of ERK1/2. U 0126 147-152 mitogen activated protein kinase 3 Rattus norvegicus 122-128 22957439-7 2012 Our results suggest that GW5074 and U0126 act as neuroprotants against 6-OHDA toxicity in PC12 cells by modulating Raf-1/ERK1/2 signaling systems. U 0126 36-41 mitogen activated protein kinase 3 Rattus norvegicus 121-127 22654119-7 2012 Interestingly, the adhesion and migration of osteoblasts were decreased when these siRNA reagents as well as the ERK1/2 signaling pathway inhibitors, U0126 and PD98059, were present. U 0126 150-155 mitogen activated protein kinase 3 Rattus norvegicus 113-119 22957439-0 2012 The Raf-1 inhibitor GW5074 and the ERK1/2 pathway inhibitor U0126 ameliorate PC12 cells apoptosis induced by 6-hydroxydopamine. U 0126 60-65 mitogen activated protein kinase 3 Rattus norvegicus 35-41 21896500-7 2012 Levels of phosphorylated extracellular signal-regulated kinase 1 and 2 (p-ERK1/2) were restored by retroviral infection of mitogen-activated protein kinase (MEK) 1/2 and reduced by U0126 in PECs exposed to high albumin levels in culture and apoptosis measured by Hoechst staining. U 0126 181-186 mitogen activated protein kinase 3 Rattus norvegicus 25-70 22285838-9 2012 Treatment of cells with the specific MEK1 inhibitor PD98059 or U0126 suppressed ERK1/2 phosphorylation and TGF-beta1 expression, and completely restored the level of STAT3 (Tyr705) phosphorylation in MAPCs cultured in HG media. U 0126 63-68 mitogen activated protein kinase 3 Rattus norvegicus 80-86 22511624-10 2012 Inhibition of ERK1/2 phosphorylation with U0126 was observed for changes in VEGF secretion. U 0126 42-47 mitogen activated protein kinase 3 Rattus norvegicus 14-20 22511624-13 2012 An ERK1/2 specific inhibitor, U0126, stopped the phosphorylation of ERK1/2, lowered AP-1 DNA binding activity, and reduced Muller cells secretion of VEGF under high glucose conditions. U 0126 30-35 mitogen activated protein kinase 3 Rattus norvegicus 3-9 22511624-13 2012 An ERK1/2 specific inhibitor, U0126, stopped the phosphorylation of ERK1/2, lowered AP-1 DNA binding activity, and reduced Muller cells secretion of VEGF under high glucose conditions. U 0126 30-35 mitogen activated protein kinase 3 Rattus norvegicus 68-74 22198514-8 2012 Specific ERK1/2 inhibitors (SB386023 and U0126) and an NF-kappaB inhibitor (wedelolactone) attenuated the mmLDL-increased ET(B) receptor-mediated contraction and ET(B) receptor mRNA and protein levels. U 0126 41-46 mitogen activated protein kinase 3 Rattus norvegicus 9-15 21896500-7 2012 Levels of phosphorylated extracellular signal-regulated kinase 1 and 2 (p-ERK1/2) were restored by retroviral infection of mitogen-activated protein kinase (MEK) 1/2 and reduced by U0126 in PECs exposed to high albumin levels in culture and apoptosis measured by Hoechst staining. U 0126 181-186 mitogen activated protein kinase 3 Rattus norvegicus 74-80 22276178-9 2012 Pharmacological inhibition of ERK1/2 phosphorylation with U0126 resulted in a decreased AAI-induced autophagy that was accompanied by an increased apoptosis. U 0126 58-63 mitogen activated protein kinase 3 Rattus norvegicus 30-36 22025495-11 2012 Significantly more phospho-ERK1/2-immunoreactive neurons in the superficial spinal dorsal horn were observed in the remifentanil 120-minute groups with hyperalgesia than in the 30-minute remifentanil groups without hyperalgesia, although U0126 did not suppress hyperalgesia. U 0126 238-243 mitogen activated protein kinase 3 Rattus norvegicus 27-33 22198183-8 2012 Silencing ERK1/2 using siRNAs and the MEK/ERK inhibitor U0126 attenuated the radiation-induced phosphorylation of GSK3beta and altered the protein levels of Snail, alpha-SMA, and E-cadherin in RLE-6TN cells. U 0126 56-61 mitogen activated protein kinase 3 Rattus norvegicus 10-16 22134701-6 2012 More importantly, U0126, a selective inhibitor of ERK1/2, mimicked the above cytoprotection of H(2)S against CoCl(2)-induced injury in H9c2 cells. U 0126 18-23 mitogen activated protein kinase 3 Rattus norvegicus 50-56 23189948-6 2012 or a selective inhibitor of ERK1/2 phosphorylation by MEK1, U0126 (5 mg/kg, i.p.) U 0126 60-65 mitogen activated protein kinase 3 Rattus norvegicus 28-34 21819443-14 2011 Cytokine-induced ERK1/2 phosphorylation and cyclin D1 expression were attenuated by U0126, suggesting that the ERK1/2 and NF-kappaB signalling pathways were involved in cardiac fibroblast proliferation. U 0126 84-89 mitogen activated protein kinase 3 Rattus norvegicus 17-23 21840963-7 2011 Inhibitors of Src kinase (PP1), PI3K (wortmannin), and ERK1/2 (U0126) all blocked the T3-induced Na-K-ATPase activity. U 0126 63-68 mitogen activated protein kinase 3 Rattus norvegicus 55-61 22375417-7 2011 pERK1/2 level was examined by Western blotting after co-cultured with optimal concentration of gastrodin and effective specific ERK1/2 pathway inhibitors PD98059, U0126. U 0126 163-168 mitogen activated protein kinase 3 Rattus norvegicus 1-7 21819443-14 2011 Cytokine-induced ERK1/2 phosphorylation and cyclin D1 expression were attenuated by U0126, suggesting that the ERK1/2 and NF-kappaB signalling pathways were involved in cardiac fibroblast proliferation. U 0126 84-89 mitogen activated protein kinase 3 Rattus norvegicus 111-117 22088530-9 2011 CONCLUSIONS: Inhibition of ERK 1/2 by U0126 decreased the ratio of p-ERK 1/2 to ERK 1/2 and expression of MUC5AC mRNA and protein. U 0126 38-43 mitogen activated protein kinase 3 Rattus norvegicus 27-34 21988724-7 2011 Dorsomorphin induced rapid and sustained ERK1/2 activation; however, dorsomorphin-mediated ERK1/2 activation and neuritogenesis were robustly inhibited in the presence of U0126 or H89, but not GW441756. U 0126 171-176 mitogen activated protein kinase 3 Rattus norvegicus 91-97 21681580-6 2011 The infusion of either MEK inhibitor U0126 or NMDA receptor antagonist MK-801 in the CeA not only suppresses the activation of ERK1/2 in the CeA but also abolishes the expression of CPP. U 0126 37-42 mitogen activated protein kinase 3 Rattus norvegicus 127-133 22088530-9 2011 CONCLUSIONS: Inhibition of ERK 1/2 by U0126 decreased the ratio of p-ERK 1/2 to ERK 1/2 and expression of MUC5AC mRNA and protein. U 0126 38-43 mitogen activated protein kinase 3 Rattus norvegicus 69-76 22088530-9 2011 CONCLUSIONS: Inhibition of ERK 1/2 by U0126 decreased the ratio of p-ERK 1/2 to ERK 1/2 and expression of MUC5AC mRNA and protein. U 0126 38-43 mitogen activated protein kinase 3 Rattus norvegicus 69-76 21104457-6 2011 We find that activation of ERK1/2 occurs in homocysteine-treated PC12 cells and blockade of ERK1/2 with U0126 abolished the homocysteine-induced cytotoxicity and inhibitory effect on endogenous H(2)S generation. U 0126 104-109 mitogen activated protein kinase 3 Rattus norvegicus 27-33 21104457-6 2011 We find that activation of ERK1/2 occurs in homocysteine-treated PC12 cells and blockade of ERK1/2 with U0126 abolished the homocysteine-induced cytotoxicity and inhibitory effect on endogenous H(2)S generation. U 0126 104-109 mitogen activated protein kinase 3 Rattus norvegicus 92-98 21624361-6 2011 C8-C1P markedly activated extracellular signal-regulated kinase 1 and 2 (ERK1/2) within 5min, and the activation could be prevented by U0126, a MEK inhibitor. U 0126 135-140 mitogen activated protein kinase 3 Rattus norvegicus 26-71 21624361-6 2011 C8-C1P markedly activated extracellular signal-regulated kinase 1 and 2 (ERK1/2) within 5min, and the activation could be prevented by U0126, a MEK inhibitor. U 0126 135-140 mitogen activated protein kinase 3 Rattus norvegicus 73-79 21354320-8 2011 U0126 prevented the endotoxin-induced increase in phosphorylated ERK1/2 and iNOS expressions. U 0126 0-5 mitogen activated protein kinase 3 Rattus norvegicus 65-71 21631569-12 2011 Pretreatment with AG490, AG1478, U0126 or EGF Ab completely or partially inhibited the proliferation of chondrocytes and activation of Erk1/2 and EGFR. U 0126 33-38 mitogen activated protein kinase 3 Rattus norvegicus 135-141 21069809-6 2011 Inhibitors of AMPK (araA), p38MAPK (SB202190), and ERK1/2 (PD98059 and U0126) but not JNK (SP600125) suppressed gAd-induced IL-6 production. U 0126 71-76 mitogen activated protein kinase 3 Rattus norvegicus 51-57 21621740-8 2011 The ERK kinase inhibitor, U0126, partially prevented the induction of PAI-1 by AGEs. U 0126 26-31 mitogen activated protein kinase 3 Rattus norvegicus 4-7 21340437-8 2011 The results showed U0126 prevented the activation of Erk1/2 maintained by GRP75, but the total Erk1/2 expression was not affected. U 0126 19-24 mitogen activated protein kinase 3 Rattus norvegicus 53-59 21496421-9 2011 U0126 blocked the preconditioning induced by dual exposure to 3vol% isoflurane (6.13% +- 1.56%, P < 0.01) and ERK1/2 activities. U 0126 0-5 mitogen activated protein kinase 3 Rattus norvegicus 113-119 21084714-5 2011 The inhibition of MAPK3/1 by U0126 did not affect the activation of MAPK14 by ET-1. U 0126 29-34 mitogen activated protein kinase 3 Rattus norvegicus 18-23 21340437-11 2011 These results suggest U0126 prevents protective effect of GRP75 on PC12 cells by inhibiting Erk1/2 phosphorylation, which certifies that GRP75 can inhibit the mitochondria-dependent apoptotic pathway through Raf/Mek/Erk1/2 signaling cascade. U 0126 22-27 mitogen activated protein kinase 3 Rattus norvegicus 92-98 21340437-11 2011 These results suggest U0126 prevents protective effect of GRP75 on PC12 cells by inhibiting Erk1/2 phosphorylation, which certifies that GRP75 can inhibit the mitochondria-dependent apoptotic pathway through Raf/Mek/Erk1/2 signaling cascade. U 0126 22-27 mitogen activated protein kinase 3 Rattus norvegicus 216-222 20967757-9 2011 Finally, we observed in primary cultured rat hepatocytes that U0126 (a selective inhibitor of MAPK/ERK kinase1/2) corrected hCRP-induced impairment of insulin signaling. U 0126 62-67 mitogen activated protein kinase 3 Rattus norvegicus 94-98 21799677-7 2011 In addition, Dilong stimulated ERK1/2 and p38 phosphorylation was attenuated by pretreatment with chemical inhibitors (U0126 and SB203580), and small interfering ERK1/2 and p38 RNA, resulting in migration and uPA-related signal pathway inhibition. U 0126 119-124 mitogen activated protein kinase 3 Rattus norvegicus 31-37 21355419-9 2010 Pretreatment with U0126 reduced GFAP and ERK1/2 expression and increased lesion volumes in response to stimulation at 10 Hz. U 0126 18-23 mitogen activated protein kinase 3 Rattus norvegicus 41-47 22076135-5 2011 The anorexigenic effects of VTA-administered leptin were also blocked by pretreatment with U0126, which effectively blocked phosphorylation of ERK1/2 but not STAT3. U 0126 91-96 mitogen activated protein kinase 3 Rattus norvegicus 143-149 20399244-11 2010 Moreover, U0126 and LY294002, pharmacological inhibitors of MEK1/2 and phosphatidylinositol 3-kinase which are upstream of ERK1/2 and Akt/protein kinase B, respectively attenuated HO-1 and GCLC expression as well as the ARE-driven transcriptional activation of Nrf2. U 0126 10-15 mitogen activated protein kinase 3 Rattus norvegicus 123-129 20535114-12 2010 ERK1/2 inhibition in vivo (U0126) prevented LF-induced diameter reduction. U 0126 27-32 mitogen activated protein kinase 3 Rattus norvegicus 0-6 20445124-9 2010 U0126, an inhibitor of ERK1/2, also downregulated VEGF expression, in addition to ERK1/2 and AP-1 activity. U 0126 0-5 mitogen activated protein kinase 3 Rattus norvegicus 23-29 20445124-9 2010 U0126, an inhibitor of ERK1/2, also downregulated VEGF expression, in addition to ERK1/2 and AP-1 activity. U 0126 0-5 mitogen activated protein kinase 3 Rattus norvegicus 82-88 20818498-4 2010 We found that U0126, a specific inhibitor of ERK1/2, and SB203580, a specific inhibitor of p38, down-regulated the TGF-beta1-induced phosphorylation of Smad2 at both linker and C-terminal sites in rat mesangial cells. U 0126 14-19 mitogen activated protein kinase 3 Rattus norvegicus 45-51 20633629-7 2010 U0126, inhibitor of ERK1/2, significantly reduced CA and RA effects on cell differentiation and AChE activity. U 0126 0-5 mitogen activated protein kinase 3 Rattus norvegicus 20-26 20215560-11 2010 PAR1 effects on ERK1/2 phosphorylation and cell migration were blocked both by pertussis toxin and by the mitogen-activated protein kinase kinase/ERK inhibitor [1,4-diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126)], whereas PAR2 effects were only blocked by U0126. U 0126 215-220 mitogen activated protein kinase 3 Rattus norvegicus 16-22 20444941-8 2010 GW5074 and U0126 inhibited the phosphorylation of ERK1/2 and NF-kappaB p65 (S536). U 0126 11-16 mitogen activated protein kinase 3 Rattus norvegicus 50-56 20403072-4 2010 Pre-treatment with U0126, a specific inhibitor of MAPK/ERK kinases 1/2 (MEK1/2), inhibited ERK1/2 phosphorylation, and significantly attenuated apoptosis and increased neuronal survival. U 0126 19-24 mitogen activated protein kinase 3 Rattus norvegicus 50-54 20403072-4 2010 Pre-treatment with U0126, a specific inhibitor of MAPK/ERK kinases 1/2 (MEK1/2), inhibited ERK1/2 phosphorylation, and significantly attenuated apoptosis and increased neuronal survival. U 0126 19-24 mitogen activated protein kinase 3 Rattus norvegicus 91-97 20412391-3 2010 The activation of ERK1/2, but not p38, is responsible for zinc neurotoxicity as only U0126, a MEK inhibitor that blocks ERK1/2 phosphorylation, significantly protects cortical neurons from zinc exposure. U 0126 85-90 mitogen activated protein kinase 3 Rattus norvegicus 18-24 20412391-3 2010 The activation of ERK1/2, but not p38, is responsible for zinc neurotoxicity as only U0126, a MEK inhibitor that blocks ERK1/2 phosphorylation, significantly protects cortical neurons from zinc exposure. U 0126 85-90 mitogen activated protein kinase 3 Rattus norvegicus 120-126 20215560-11 2010 PAR1 effects on ERK1/2 phosphorylation and cell migration were blocked both by pertussis toxin and by the mitogen-activated protein kinase kinase/ERK inhibitor [1,4-diamino-2,3-dicyano-1,4-bis(methylthio)butadiene (U0126)], whereas PAR2 effects were only blocked by U0126. U 0126 266-271 mitogen activated protein kinase 3 Rattus norvegicus 16-22 21063091-5 2010 Although preventing ERK1/2- p90RSK signaling pathway (10 mumol/L U0126) mimicked SIL effect, SIL did not blunt the acidosis-mediated increase in kinases activation. U 0126 65-70 mitogen activated protein kinase 3 Rattus norvegicus 20-26 20331962-6 2010 We found that N/OFQ, PDBu, and IDB increased the amount of phosphorylated ERK-1/2 and Elk-1; U0126, a specific inhibitor for ERK-1/2, attenuated the inhibitory effect of N/OFQ on the I(K). U 0126 93-98 mitogen activated protein kinase 3 Rattus norvegicus 74-81 20331962-6 2010 We found that N/OFQ, PDBu, and IDB increased the amount of phosphorylated ERK-1/2 and Elk-1; U0126, a specific inhibitor for ERK-1/2, attenuated the inhibitory effect of N/OFQ on the I(K). U 0126 93-98 mitogen activated protein kinase 3 Rattus norvegicus 125-132 19936794-8 2010 Inhibition of mitogen-activated protein kinase-Erk1/2 signaling using an Erk1/2-specific inhibitor (UO126) abolished SCCM-induced Erk1/2 phosphorylation and neuritogenesis completely. U 0126 100-105 mitogen activated protein kinase 3 Rattus norvegicus 47-53 19936794-8 2010 Inhibition of mitogen-activated protein kinase-Erk1/2 signaling using an Erk1/2-specific inhibitor (UO126) abolished SCCM-induced Erk1/2 phosphorylation and neuritogenesis completely. U 0126 100-105 mitogen activated protein kinase 3 Rattus norvegicus 73-79 19936794-8 2010 Inhibition of mitogen-activated protein kinase-Erk1/2 signaling using an Erk1/2-specific inhibitor (UO126) abolished SCCM-induced Erk1/2 phosphorylation and neuritogenesis completely. U 0126 100-105 mitogen activated protein kinase 3 Rattus norvegicus 73-79 19910580-7 2010 Inhibition of ERK1/2 by U0126/PD-98059 or overexpression of a dominant negative p53 comparably inhibited S100B-induced myocyte apoptosis. U 0126 24-29 mitogen activated protein kinase 3 Rattus norvegicus 14-20 19684256-7 2009 However, repeated coadministration of U0126 and morphine into the PAG blocked ERK1/2 phosphorylation and enhanced the development of morphine tolerance. U 0126 38-43 mitogen activated protein kinase 3 Rattus norvegicus 78-84 19948989-14 2010 Extracellular signal-regulated kinase 1/2 inhibition in vivo (U0126) prevented hypertrophy in high-flow arteries. U 0126 62-67 mitogen activated protein kinase 3 Rattus norvegicus 0-41 19819736-4 2009 Two study groups, neurons displaying epileptiform activity and the same neurons treated with ERK1/2 inhibitor U0126, were studied at six time points, 0 min, 30 min, 2h, 6h, 12h, and 24h following discharge. U 0126 110-115 mitogen activated protein kinase 3 Rattus norvegicus 93-99 19469685-6 2009 The data further showed that TMT increased phosphorylation of Erk1/2 in the motor cortex as well as the spinal cord injury area, and inhibition of Erk1/2 activity by administration of the MEK1 inhibitors PD98059 and U0126 reduced collateral outgrowth of descending CST axons in TMT animals. U 0126 216-221 mitogen activated protein kinase 3 Rattus norvegicus 147-153 19548254-3 2009 The increase in lipolysis with Oligonol was prevented completely by pretreatment with either PD98059 or U0126, selective ERK1/2 inhibitors, which also prevented the reduction in the expression of perilipin protein. U 0126 104-109 mitogen activated protein kinase 3 Rattus norvegicus 121-127 19631230-8 2009 Inhibition of ERK1/2 kinase with U0126 reduced both cell death and ROS formation, suggesting that ERK1/2 activation is involved in OH-PCB toxicity. U 0126 33-38 mitogen activated protein kinase 3 Rattus norvegicus 14-20 19631230-8 2009 Inhibition of ERK1/2 kinase with U0126 reduced both cell death and ROS formation, suggesting that ERK1/2 activation is involved in OH-PCB toxicity. U 0126 33-38 mitogen activated protein kinase 3 Rattus norvegicus 98-104 19497125-5 2009 The specific MEK1/2 inhibitor U0126, given intraperitoneal zero or 6 hours after the ischemic event, reduced the infarct volume significantly (11.8 +/- 2% and 14.6 +/- 3%, respectively; P < 0.05), improved neurological function, normalized expression of phosphorylated ERK1/2, and reduced expression of MMP-9 and TIMP-1 in the vessel walls. U 0126 30-35 mitogen activated protein kinase 3 Rattus norvegicus 272-278 19470835-6 2009 Pretreatment with UO126 abolished the combined effects, demonstrating Erk1/2 requirement. U 0126 18-23 mitogen activated protein kinase 3 Rattus norvegicus 70-76 19419999-3 2009 The MEK/ERK inhibitor U0126 abolished phosphorylation of NHE1 and p90(RSK) as well as ERK1/2. U 0126 22-27 mitogen activated protein kinase 3 Rattus norvegicus 86-92 19359388-5 2009 Progesterone-induced proliferation was not dependent on conversion to metabolites and was antagonized by the ERK(1/2) inhibitor UO126. U 0126 128-133 mitogen activated protein kinase 3 Rattus norvegicus 109-116 19533291-4 2009 SC-1 alone induced neuronal differentiation through extracellular signal-regulated kinase (ERK) 1/2 activation that is essential for nerve growth factor (NGF)-induced neuronal differentiation, as shown by the suppression with MEK1/2 inhibitors, PD98059 and U0126. U 0126 257-262 mitogen activated protein kinase 3 Rattus norvegicus 52-99 19581298-5 2009 U0126, at 30 mum, that blocks ERK1/2 signaling selectively attenuated neurite outgrowth induced by NGF and Bt(2)cAMP, but BIX02188 and BIX02189, at 30 mum, that block ERK5 signaling and an ERK5 dominant-negative mutant suppressed only NGF-induced neurite outgrowth. U 0126 0-5 mitogen activated protein kinase 3 Rattus norvegicus 30-36 18584900-3 2009 RESULTS: E(2)-promoted VSMC proliferation was accompanied with an increased phosphorylation of ERK1/2, which could be blocked by MEK inhibitor U0126; the E(2)-induced VSMC apoptosis, which appeared mainly in the G2/M phase, was related with the activation of p38 and could be blocked by p38 inhibitor SB203580. U 0126 143-148 mitogen activated protein kinase 3 Rattus norvegicus 95-101 19151362-7 2009 U0126, a specific inhibitor of MEK1/2, the upstream activator of ERK1/2, abolishes HDL- and S1P-induced Stat3 activation, whereas the p38 MAPK blocker SB203580 has no significant effect. U 0126 0-5 mitogen activated protein kinase 3 Rattus norvegicus 65-71 19176891-5 2009 Using Western blot analysis, we show that the robust increase in tyrosine hydroxylase phosphorylation obtained with intraperitoneal CCK is significantly attenuated in rats pretreated with the ERK-pathway blocker U0126 injected into the 4th ventricle. U 0126 212-217 mitogen activated protein kinase 3 Rattus norvegicus 192-195 19187440-3 2009 iNOS expression was attenuated by the MAPK/extracellular signal-regulated kinase pathway inhibitor U0126 and the phosphorylated forms of extracellular signal-regulated kinase 1 and 2 were detectable in microglia treated with albumin or fraction V. Glutamate release was prevented by l-alpha-aminoadipate and glutathione levels in microglia rose on exposure to albumin. U 0126 99-104 mitogen activated protein kinase 3 Rattus norvegicus 38-42 19471096-7 2009 On the contrary, ERK1/2 affects cytoskeleton organization and focal complexes assembly during H/R, since U0126 improved actin and tubulin cytoskeleton structure, reduced cell contraction and prevented paxillin redistribution. U 0126 105-110 mitogen activated protein kinase 3 Rattus norvegicus 17-23 19084521-7 2009 U0126, a mitogen-activated protein/extracellular signal-regulated kinase 1 and 2 inhibitor, partially blocked the rescue effect of latnanoprost acid (p=0.013). U 0126 0-5 mitogen activated protein kinase 3 Rattus norvegicus 35-80 19000637-6 2009 By showing the direct suppression of extracellular signaling-regulated kinase1/2 (ERK1/2) of TG cells treated with U0126, known to suppress the activation of ERK1/2, and significant synergistic effects between PVA and U0126, we demonstrated the suppression of ERK1/2 pathway is one of the effects of PVA-promoted TG cell differentiation and mineralization. U 0126 115-120 mitogen activated protein kinase 3 Rattus norvegicus 82-88 19000637-6 2009 By showing the direct suppression of extracellular signaling-regulated kinase1/2 (ERK1/2) of TG cells treated with U0126, known to suppress the activation of ERK1/2, and significant synergistic effects between PVA and U0126, we demonstrated the suppression of ERK1/2 pathway is one of the effects of PVA-promoted TG cell differentiation and mineralization. U 0126 115-120 mitogen activated protein kinase 3 Rattus norvegicus 158-164 19000637-6 2009 By showing the direct suppression of extracellular signaling-regulated kinase1/2 (ERK1/2) of TG cells treated with U0126, known to suppress the activation of ERK1/2, and significant synergistic effects between PVA and U0126, we demonstrated the suppression of ERK1/2 pathway is one of the effects of PVA-promoted TG cell differentiation and mineralization. U 0126 115-120 mitogen activated protein kinase 3 Rattus norvegicus 158-164 19000637-6 2009 By showing the direct suppression of extracellular signaling-regulated kinase1/2 (ERK1/2) of TG cells treated with U0126, known to suppress the activation of ERK1/2, and significant synergistic effects between PVA and U0126, we demonstrated the suppression of ERK1/2 pathway is one of the effects of PVA-promoted TG cell differentiation and mineralization. U 0126 218-223 mitogen activated protein kinase 3 Rattus norvegicus 82-88 19063870-3 2009 The ERK1/2 inhibitor, U0126, injected at ischemia onset, attenuated the increase in phosphorylated ERK1/2 (P-ERK1/2) after reperfusion. U 0126 22-27 mitogen activated protein kinase 3 Rattus norvegicus 4-10 19063870-3 2009 The ERK1/2 inhibitor, U0126, injected at ischemia onset, attenuated the increase in phosphorylated ERK1/2 (P-ERK1/2) after reperfusion. U 0126 22-27 mitogen activated protein kinase 3 Rattus norvegicus 99-105 19063870-3 2009 The ERK1/2 inhibitor, U0126, injected at ischemia onset, attenuated the increase in phosphorylated ERK1/2 (P-ERK1/2) after reperfusion. U 0126 22-27 mitogen activated protein kinase 3 Rattus norvegicus 99-105 19080332-3 2008 The aim of this study was to investigate interactions and cross-talks between MEK1/2-extracellular signal-related kinase (ERK1/2) signaling and G protein-couple signaling in synoviocytes of collagen-induced arthritis (CIA) rats by the stimulation of interleukin-1 (IL-1), U0126, isoprenaline hydrochloride and aminophylline respectively. U 0126 272-277 mitogen activated protein kinase 3 Rattus norvegicus 122-128 19590238-9 2009 YB-1-stimulated cell proliferation was blocked by U0126, a specific inhibitor of ERK1/2. U 0126 50-55 mitogen activated protein kinase 3 Rattus norvegicus 81-87 19590238-10 2009 ERK1/2 regulated YB-1 expression in MCs stimulated with TGF-beta, an effect that was inhibited by U0126. U 0126 98-103 mitogen activated protein kinase 3 Rattus norvegicus 0-6 18775851-6 2008 The functional importance of ERK1/2 and p53 in doxorubicin-induced toxicity was further demonstrated by the specific ERK inhibitor U-0126 and p53 inhibitor pifithrin (PFT)-alpha, which abrogated the changes in Bcl-2 family proteins and cell death produced by doxorubicin. U 0126 131-137 mitogen activated protein kinase 3 Rattus norvegicus 29-35 18828601-6 2008 The inhibition of GJIC and phosphorylation of Cx43 and ERK1/2 by EGCG were completely blocked by U0126, a pharmacological inhibitor of mitogen-activated protein kinase/ERK kinase. U 0126 97-102 mitogen activated protein kinase 3 Rattus norvegicus 55-61 18828601-6 2008 The inhibition of GJIC and phosphorylation of Cx43 and ERK1/2 by EGCG were completely blocked by U0126, a pharmacological inhibitor of mitogen-activated protein kinase/ERK kinase. U 0126 97-102 mitogen activated protein kinase 3 Rattus norvegicus 55-58 18701654-6 2008 Azide"s effect on p-ERK1/2 abundance and glucose transport in Clone 9 cells was partially abolished by the MEK1/2 inhibitor U0126. U 0126 124-129 mitogen activated protein kinase 3 Rattus norvegicus 20-26 18775851-7 2008 U-0126 blocked the phosphorylation and nuclear translocation of both ERK1/2 and p53, whereas PFT-alpha blocked only the changes in p53. U 0126 0-6 mitogen activated protein kinase 3 Rattus norvegicus 69-75 18573356-10 2008 U0126, an inhibitor of ERK1/2, blocked the increase in osteogenesis markers. U 0126 0-5 mitogen activated protein kinase 3 Rattus norvegicus 23-29 18457920-9 2008 The induction of c-fos, c-jun, nur77, and zif268 by hypoxia was inhibited by naloxone (0.1 microM) and MAPK inhibitors (10 microM of U0126, D98059, SB203580). U 0126 133-138 mitogen activated protein kinase 3 Rattus norvegicus 103-107 18574076-4 2008 Intracerebroventricular administration of PD98059 and UO126, 2 selective p44/42 MAPK inhibitors, induced significant decreases in mean arterial pressure, heart rate, and renal sympathetic nerve activity in HF rats, but had no effect on these variables in sham-operated rats. U 0126 54-59 mitogen activated protein kinase 3 Rattus norvegicus 73-76 19100107-6 2008 These effects could be significantly blocked by both PI3K inhibitor, LY294002 and ERK1/2 inhibitor, U0126. U 0126 100-105 mitogen activated protein kinase 3 Rattus norvegicus 82-88 18583239-3 2008 In another experiment, the cells were preincubated for 1 h in the presence of U0126 (an inhibitor of the MAPK/ERK kinase), irbesartan (an AT-1 receptor blocker), or antioxidant-N-acetylcysteine (NAC) prior to AngII exposure, and the protein expression of phospho-P42/44 and PDGF-B were measured with Western blotting. U 0126 78-83 mitogen activated protein kinase 3 Rattus norvegicus 105-109 18771612-5 2008 RESULTS: U0126, but not SB203580 could inhibit the activation of ERK1/2 induced by electromagnetic exposure. U 0126 9-14 mitogen activated protein kinase 3 Rattus norvegicus 65-71 18295205-10 2008 Inhibition of MAPK with U0126 also blocked secretion stimulated by OPC-12759. U 0126 24-29 mitogen activated protein kinase 3 Rattus norvegicus 14-18 18339311-3 2008 EGF increased the phosphorylation of ERK1/2 and TRPM6 expression that were inhibited by U0126 in renal epithelial NRK-52E cells. U 0126 88-93 mitogen activated protein kinase 3 Rattus norvegicus 37-43 17902169-5 2008 In accordance with these findings, S1P stimulated phosphorylation of p42/p44 MAPK and Akt which was attenuated by U0126 and wortmannin, respectively. U 0126 114-119 mitogen activated protein kinase 3 Rattus norvegicus 73-81 18191957-5 2008 RS-induced SRP and ERK 1/2 phosphorylation were both abolished by pretreatment of U0126 (MEK inhibitor). U 0126 82-87 mitogen activated protein kinase 3 Rattus norvegicus 19-26 18339080-14 2008 By blocking the extracellular signal-regulated protein kinase (ERK1/2) activation by adding U0126, we could prevent the apoptosis induced by atorvastatin. U 0126 92-97 mitogen activated protein kinase 3 Rattus norvegicus 63-69 17943186-4 2008 The hyperplasia and hyaluronan production induced by all-trans RA were blocked with (1) AG1478, an inhibitor of the EGFR; (2) UO126, an inhibitor of the MAPK/ERK kinase, and (3) GM6001, an inhibitor of the matrix metalloproteinases. U 0126 126-131 mitogen activated protein kinase 3 Rattus norvegicus 153-157 17943186-4 2008 The hyperplasia and hyaluronan production induced by all-trans RA were blocked with (1) AG1478, an inhibitor of the EGFR; (2) UO126, an inhibitor of the MAPK/ERK kinase, and (3) GM6001, an inhibitor of the matrix metalloproteinases. U 0126 126-131 mitogen activated protein kinase 3 Rattus norvegicus 158-161 18054051-8 2008 U0126 blocked the gallic-acid-induced phosphorylation of Cx43 and ERK1/2, indicating that the gallic-acid-induced inhibition of GJIC is mediated by phosphorylation of Cx43 via activation of ERK1/2. U 0126 0-5 mitogen activated protein kinase 3 Rattus norvegicus 66-72 17918745-2 2008 The ebselen-induced MAPK activation was suppressed by U0126, an inhibitor of MAPK kinase (MEK1/2), but not by K252a, a selective inhibitor of Trk family tyrosine kinases; AG1478, an antagonist of epidermal growth factor receptor (EGFR); pertussis toxin, an inhibitor of Gi/o; or GP antagonist-2A, an inhibitor of Gq. U 0126 54-59 mitogen activated protein kinase 3 Rattus norvegicus 20-24 17918745-2 2008 The ebselen-induced MAPK activation was suppressed by U0126, an inhibitor of MAPK kinase (MEK1/2), but not by K252a, a selective inhibitor of Trk family tyrosine kinases; AG1478, an antagonist of epidermal growth factor receptor (EGFR); pertussis toxin, an inhibitor of Gi/o; or GP antagonist-2A, an inhibitor of Gq. U 0126 54-59 mitogen activated protein kinase 3 Rattus norvegicus 77-81 17706224-9 2008 This is supported by experiments with specific inhibitors for c-Jun-NH(2)-terminal kinase (SP600125), extracellular signal-regulated kinase 1 and 2 (PD98059 and U0126) and p38 (SB203580) that had no inhibitory effect on the up-regulation of TP receptors. U 0126 161-166 mitogen activated protein kinase 3 Rattus norvegicus 102-147 18054051-8 2008 U0126 blocked the gallic-acid-induced phosphorylation of Cx43 and ERK1/2, indicating that the gallic-acid-induced inhibition of GJIC is mediated by phosphorylation of Cx43 via activation of ERK1/2. U 0126 0-5 mitogen activated protein kinase 3 Rattus norvegicus 190-196 18275597-4 2008 IEGs exhibited differential temporal and transient regulation, with expression of second phase RNAs within 1 h. Of transcripts upregulated at 30 minutes encoding established proteins, 28 were inhibited >50% by U0126 (which inhibits ERK1/2/5 signaling), with 9 inhibited 25-50%. U 0126 213-218 mitogen activated protein kinase 3 Rattus norvegicus 235-241 17928626-7 2008 MAPK3/1 phosphorylation was also decreased in the presence of AG 1478, an inhibitor of the epidermal growth factor receptor (EGFR) kinase, and in the presence of MAP2K1/2 inhibitor UO126. U 0126 181-186 mitogen activated protein kinase 3 Rattus norvegicus 0-5 17067562-6 2007 We further observed that the extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor U0126 abolishes PGE2-induced Stat3 activation whereas the p38 MAP kinase blocker SB203580 has no effect. U 0126 90-95 mitogen activated protein kinase 3 Rattus norvegicus 29-70 17497701-8 2008 Furthermore, the antiapoptotic effect of lovastatin on mitochondrial apoptotic pathway was effectively abrogated by both PI3K inhibitor, LY294002 and ERK1/2 inhibitor, U0126. U 0126 168-173 mitogen activated protein kinase 3 Rattus norvegicus 150-156 17868299-8 2007 The MEK inhibitor U0126 applied together with EUK-189 or EUK-207 completely blocked ERK1/2 activation, but had no effect on their protective effects against OGD-induced LDH release. U 0126 18-23 mitogen activated protein kinase 3 Rattus norvegicus 84-90 17694254-6 2007 LY294002 and UO126, inhibitors of PI3K-Akt and p44/42 phosphorylation respectively, abolished the protective effects of apelin-13 in vitro.Western blot analysis provided further evidence for the involvement of PI3K-Akt and p44/42 in the cardioprotective actions of apelin. U 0126 13-18 mitogen activated protein kinase 3 Rattus norvegicus 47-50 17694254-6 2007 LY294002 and UO126, inhibitors of PI3K-Akt and p44/42 phosphorylation respectively, abolished the protective effects of apelin-13 in vitro.Western blot analysis provided further evidence for the involvement of PI3K-Akt and p44/42 in the cardioprotective actions of apelin. U 0126 13-18 mitogen activated protein kinase 3 Rattus norvegicus 223-226 17265428-7 2007 U0126, a selective inhibitor of ERK1/2, completely blocked Runx2 activation during periods of mechanical stress, but the p38 MAPK-selective inhibitor SB203580 did not alter nuclear phosphorylation of Runx2. U 0126 0-5 mitogen activated protein kinase 3 Rattus norvegicus 32-38 17558277-3 2007 The Erk1/2 inhibitor U0126 inhibited both the increase in p-Erk1/2 and the bromodeoxy uridine incorporation. U 0126 21-26 mitogen activated protein kinase 3 Rattus norvegicus 4-10 17558277-3 2007 The Erk1/2 inhibitor U0126 inhibited both the increase in p-Erk1/2 and the bromodeoxy uridine incorporation. U 0126 21-26 mitogen activated protein kinase 3 Rattus norvegicus 60-66 17212361-6 2007 Blockade of ERK signaling by the mitogen-activated protein kinase kinase (MEK) inhibitor, U0126, suppressed both glucose- and insulin-induced ERK 1/2 phosphorylation and PSC proliferation. U 0126 90-95 mitogen activated protein kinase 3 Rattus norvegicus 12-15 17212361-6 2007 Blockade of ERK signaling by the mitogen-activated protein kinase kinase (MEK) inhibitor, U0126, suppressed both glucose- and insulin-induced ERK 1/2 phosphorylation and PSC proliferation. U 0126 90-95 mitogen activated protein kinase 3 Rattus norvegicus 142-147 17382630-5 2007 In the U0126-treated group, rats were pretreated with a specific inhibitor of the mitogen-activated protein kinase/extracellular signal-regulated kinases 1 and 2, U0126, to inhibit extracellular signal-regulated kinases 1 and 2 phosphorylation. U 0126 7-12 mitogen activated protein kinase 3 Rattus norvegicus 115-161 17382630-5 2007 In the U0126-treated group, rats were pretreated with a specific inhibitor of the mitogen-activated protein kinase/extracellular signal-regulated kinases 1 and 2, U0126, to inhibit extracellular signal-regulated kinases 1 and 2 phosphorylation. U 0126 7-12 mitogen activated protein kinase 3 Rattus norvegicus 181-227 17382630-5 2007 In the U0126-treated group, rats were pretreated with a specific inhibitor of the mitogen-activated protein kinase/extracellular signal-regulated kinases 1 and 2, U0126, to inhibit extracellular signal-regulated kinases 1 and 2 phosphorylation. U 0126 163-168 mitogen activated protein kinase 3 Rattus norvegicus 115-161 17382630-5 2007 In the U0126-treated group, rats were pretreated with a specific inhibitor of the mitogen-activated protein kinase/extracellular signal-regulated kinases 1 and 2, U0126, to inhibit extracellular signal-regulated kinases 1 and 2 phosphorylation. U 0126 163-168 mitogen activated protein kinase 3 Rattus norvegicus 181-227 17382630-9 2007 In the U0126 group, U0126 treatment completely blocked extracellular signal-regulated kinases 1 and 2 phosphorylation. U 0126 7-12 mitogen activated protein kinase 3 Rattus norvegicus 55-101 17382630-9 2007 In the U0126 group, U0126 treatment completely blocked extracellular signal-regulated kinases 1 and 2 phosphorylation. U 0126 20-25 mitogen activated protein kinase 3 Rattus norvegicus 55-101 16888810-5 2007 In addition, pre-exposure to U0126, a specific inhibitor of the ERK1/2 signaling, prevented nicotine-mediated anti-apoptotic effects. U 0126 29-34 mitogen activated protein kinase 3 Rattus norvegicus 64-70 17126295-8 2007 The activation of MAPK by CSs 1-3 was suppressed by U0126, a MEK inhibitor, but not by K252a, an inhibitor of TrkA; AG1478, an antagonist of epidermal growth factor receptor (EGFR); or by pertussis toxin. U 0126 52-57 mitogen activated protein kinase 3 Rattus norvegicus 18-22 17497701-10 2008 The activation of ERK1/2 was inhibited by a PI3K inhibitor, LY294002, but U0126, a ERK1/2 inhibitor did not inhibit phosphorylation of Akt and GSK3 beta. U 0126 74-79 mitogen activated protein kinase 3 Rattus norvegicus 83-89 17996850-7 2007 Pretreatment of U-0126 (MEK1/2 inhibitor) completely abolished the GSK-3beta inhibition-induced phosphorylation of ERK1/2. U 0126 16-22 mitogen activated protein kinase 3 Rattus norvegicus 115-121 17686496-9 2007 Inhibition of the ERK1/2 activation by U0126 diminished these effects of lithium. U 0126 39-44 mitogen activated protein kinase 3 Rattus norvegicus 18-24 17537430-5 2007 Moreover, 4-AP increased the expressions of p-ERK1/2 in cultured PASMCs s and whole tissues, which were prevented by pretreatment of the cells or tissues with U0126. U 0126 159-164 mitogen activated protein kinase 3 Rattus norvegicus 46-52 17524662-6 2007 These effects of endotoxin were prevented by selective inhibition of ERK1/2 phosphorylation by MAPK kinase (MEK1/2) with U0126 (5 mg kg(-1), i.p. U 0126 121-126 mitogen activated protein kinase 3 Rattus norvegicus 69-75 17524662-8 2007 Endotoxin also caused an increase in protein levels of phosphorylated ERK1/2 in aorta which was abolished by U0126. U 0126 109-114 mitogen activated protein kinase 3 Rattus norvegicus 70-76 17308007-8 2007 MAPK/ERK1/2 (MEK1/2)-ERK1/2 signaling pathway inhibitors, PD-98059 (10 micromol/l), and U-0126 (10 micromol/l), significantly reduced the phosphorylation of ERK1/2, superoxide generation (P<0.01), and spontaneous tone (P<0.01) in HT. U 0126 88-94 mitogen activated protein kinase 3 Rattus norvegicus 5-11 17308007-8 2007 MAPK/ERK1/2 (MEK1/2)-ERK1/2 signaling pathway inhibitors, PD-98059 (10 micromol/l), and U-0126 (10 micromol/l), significantly reduced the phosphorylation of ERK1/2, superoxide generation (P<0.01), and spontaneous tone (P<0.01) in HT. U 0126 88-94 mitogen activated protein kinase 3 Rattus norvegicus 21-27 17308007-8 2007 MAPK/ERK1/2 (MEK1/2)-ERK1/2 signaling pathway inhibitors, PD-98059 (10 micromol/l), and U-0126 (10 micromol/l), significantly reduced the phosphorylation of ERK1/2, superoxide generation (P<0.01), and spontaneous tone (P<0.01) in HT. U 0126 88-94 mitogen activated protein kinase 3 Rattus norvegicus 21-27 17308007-11 2007 These data suggest that inhibition of ERK1/2 signaling pathway, via PD-98059 or U-0126, may regulate spontaneous tone in an endothelium-dependent manner. U 0126 80-86 mitogen activated protein kinase 3 Rattus norvegicus 38-44 17452290-6 2007 Interestingly, the PMA-induced CREB phosphorylation was also blocked by a calcium/calmodulin-dependent protein kinase inhibitor KN93 and the two mitogen-activated protein kinase (MAPK) kinase inhibitors PD98059 and U0126, but not by a p38 MAPK inhibitor SB203580. U 0126 215-220 mitogen activated protein kinase 3 Rattus norvegicus 179-183 17091294-12 2007 Immunohistochemistry showed that there were lower protein levels of phosphorylated extracellular signal-regulated kinases (ERK)1/2 and phosphorylated transcription factor Elk-1 in the U0126-treated rats compared to control. U 0126 184-189 mitogen activated protein kinase 3 Rattus norvegicus 83-130 17091294-14 2007 The vascular effects of U0126 provide new perspective on possible mechanisms of actions of MAPK inhibition in cerebral ischaemia. U 0126 24-29 mitogen activated protein kinase 3 Rattus norvegicus 91-95 17170099-7 2007 LRH-1 expression induced by the heat treatment was completely inhibited by the addition of ERK inhibitor U0126 in the culture, indicating that the heat-induced LRH-1 expression in the Sertoli cells may be regulated via ERK1/2 activation pathway. U 0126 105-110 mitogen activated protein kinase 3 Rattus norvegicus 219-225 16968890-7 2007 Studies with an inhibitor of MAPK/ERK kinase (U0126) demonstrate that the inhibitory effects of U0126 on MCP-1 production are attenuated in HO-1 OE cells. U 0126 46-51 mitogen activated protein kinase 3 Rattus norvegicus 29-33 16968890-7 2007 Studies with an inhibitor of MAPK/ERK kinase (U0126) demonstrate that the inhibitory effects of U0126 on MCP-1 production are attenuated in HO-1 OE cells. U 0126 96-101 mitogen activated protein kinase 3 Rattus norvegicus 29-33 17067562-6 2007 We further observed that the extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor U0126 abolishes PGE2-induced Stat3 activation whereas the p38 MAP kinase blocker SB203580 has no effect. U 0126 90-95 mitogen activated protein kinase 3 Rattus norvegicus 72-78 16839545-4 2006 UO126, a mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase kinase (MEK) 1 and 2 inhibitor reversed this effect. U 0126 0-5 mitogen activated protein kinase 3 Rattus norvegicus 43-47 16798728-8 2006 Inhibition of ERK1/2 and Akt activity by U-0126 and LY-294002, respectively, increased TNF-alpha-induced apoptosis. U 0126 41-47 mitogen activated protein kinase 3 Rattus norvegicus 14-20 17218971-3 2006 Our data showed that 15-HETE upregulated ERK1/2 phosphorylation in a dose-dependent manner, which could be blocked by ERK pathway inhibitors U0126 and PD98059. U 0126 141-146 mitogen activated protein kinase 3 Rattus norvegicus 41-47 16712881-5 2006 On the other hand, attenuation of the spinal ERK phosphorylation by the MAPK kinase (MEK) inhibitor U0126 also could inhibit the increase of nNOS and iNOS expression in the spinal cord of morphine withdrawal rats. U 0126 100-105 mitogen activated protein kinase 3 Rattus norvegicus 72-76 16960431-10 2006 The Raf-1 kinase inhibitor and U0126 also suppressed ERK1/2 activation in nuclear fractions prepared from slices treated with zinc. U 0126 31-36 mitogen activated protein kinase 3 Rattus norvegicus 53-59 16847434-8 2006 Protection was blocked by either LY294002 or UO126, inhibitors of Akt and p44/42 MAPK, respectively. U 0126 45-50 mitogen activated protein kinase 3 Rattus norvegicus 74-77 16452470-5 2006 MEK inhibitor U0126 abolished nicotine-induced rise in P-ERK1/2, but not P-CREB, nor did it inhibit nicotine-evoked elevation in TH promoter activity, indicating that ERK1/2 was not needed for induction of TH gene expression by nicotine. U 0126 14-19 mitogen activated protein kinase 3 Rattus norvegicus 57-63 16508949-6 2006 In accordance with these findings, S1P stimulated phosphorylation of p42/p44 MAPK and Akt, which was attenuated by U0126, LY294002, or wortmannin, respectively. U 0126 115-120 mitogen activated protein kinase 3 Rattus norvegicus 73-76 16508949-6 2006 In accordance with these findings, S1P stimulated phosphorylation of p42/p44 MAPK and Akt, which was attenuated by U0126, LY294002, or wortmannin, respectively. U 0126 115-120 mitogen activated protein kinase 3 Rattus norvegicus 77-81 16448751-7 2006 The non-competitive NMDA-receptor antagonist, MK-801, and a specific inhibitor of the ERK1/2 pathway, U0126, significantly attenuated the injury-elicited increases in Homer1a mRNA when compared to saline-treated animals. U 0126 102-107 mitogen activated protein kinase 3 Rattus norvegicus 86-92 16457817-8 2006 U0126 titering experiments, furthermore, revealed that the same MEK inhibitor concentration that blocked the TGF-beta1 increase in ERK1/2 phosphorylation (20 microM) also effectively attenuated the PAI-1 inductive response suggesting a requirement for stimulated ERK signaling in TGF-beta1-mediated PAI-1 expression. U 0126 0-5 mitogen activated protein kinase 3 Rattus norvegicus 131-137 16614393-5 2006 The activation of MAPK by GLPE was suppressed by AG1478, an antagonist of epidermal growth factor receptor (EGFR), and by U0126, an inhibitor of MAPK kinase (MEK1/2), but not by K252a, an inhibitor of TrkA, or by pertussis toxin. U 0126 122-127 mitogen activated protein kinase 3 Rattus norvegicus 18-22 16614393-5 2006 The activation of MAPK by GLPE was suppressed by AG1478, an antagonist of epidermal growth factor receptor (EGFR), and by U0126, an inhibitor of MAPK kinase (MEK1/2), but not by K252a, an inhibitor of TrkA, or by pertussis toxin. U 0126 122-127 mitogen activated protein kinase 3 Rattus norvegicus 145-149 16480888-5 2006 ERK1/2-inhibitor, U0126, reduced brain ischemia but not cytokine induction. U 0126 18-23 mitogen activated protein kinase 3 Rattus norvegicus 0-6 16515552-10 2006 Moreover, caspase-3 activation triggered by TTR aggregates was abrogated by U0126, a MEK1/2 inhibitor, indicating that ERK1/2 activation is essential for TTR aggregates-induced cytotoxicity. U 0126 76-81 mitogen activated protein kinase 3 Rattus norvegicus 119-125 16630308-5 2006 These three parameters, and the phosphorylated ERK-1 protein products of H9c2 cells treated with P. gingivalis medium, were all significantly reduced after pre-administration of U0126. U 0126 178-183 mitogen activated protein kinase 3 Rattus norvegicus 47-52 16005925-5 2006 Synthetic inhibitors of ERK1/2 activation (U0126) or p38 kinase activity (SB203580) prevented both apoptosis and induction of p53 phosphorylation by DBalP. U 0126 43-48 mitogen activated protein kinase 3 Rattus norvegicus 24-30 16302187-5 2005 Immunoblot analysis demonstrated that Cx43 and the mitogen-activated protein kinase (MAPK), ERK-1/2, were phosphorylated in response to TrkA activation via NGF and that phosphorylation could be prevented by treatment with the MEK-1/2 inhibitor U0126. U 0126 244-249 mitogen activated protein kinase 3 Rattus norvegicus 92-99 16155909-5 2006 To determine whether age-related activation of ERK1/2-AP-1 signaling is responsible for the up-regulation of GCLC, the MEK inhibitors, PD98059 and U0126, were used to block ERK1/2 in VSMC from old rats. U 0126 147-152 mitogen activated protein kinase 3 Rattus norvegicus 173-179 16343798-6 2006 Pretreatment with U0126 in CIH rats significantly decreased ERK1/2 immunoreactive cells. U 0126 18-23 mitogen activated protein kinase 3 Rattus norvegicus 60-66 16343798-9 2006 Treatment with U0126 significantly reduced phospho-ERK1/2 in the CIH group. U 0126 15-20 mitogen activated protein kinase 3 Rattus norvegicus 51-57 16179908-11 2005 Furthermore, JNK and ERK were activated by H2O2 and their specific inhibitors SP600125 (for JNK) and U0126 (for ERK1/2) prevented p21Cip1 expression and blocked cell cycle arrest. U 0126 101-106 mitogen activated protein kinase 3 Rattus norvegicus 112-118 16535835-6 2005 RESULTS: The results showed that the apoptosis induced by CdCl2 inclined to enhance with dose dependent manner, Further more, U0126 and SB203580, the specific inhibitor of ERK1/2 and p38 MAPK respectively, could decrease the expression of TUNEL-positive cells significantly and lower apoptotic rate of primary cultured anterior pituitary cells. U 0126 126-131 mitogen activated protein kinase 3 Rattus norvegicus 172-178 16535835-6 2005 RESULTS: The results showed that the apoptosis induced by CdCl2 inclined to enhance with dose dependent manner, Further more, U0126 and SB203580, the specific inhibitor of ERK1/2 and p38 MAPK respectively, could decrease the expression of TUNEL-positive cells significantly and lower apoptotic rate of primary cultured anterior pituitary cells. U 0126 126-131 mitogen activated protein kinase 3 Rattus norvegicus 187-191 16123166-8 2005 Rapid E(2)-induced increases in pERK immunoreactivity were specific to the ERK1/2 pathway as demonstrated by coinjection of the mitogen-activated, ERK-activating kinase (MEK)1/2 inhibitor U0126. U 0126 188-193 mitogen activated protein kinase 3 Rattus norvegicus 75-81 15961554-7 2005 Prior administration of the MAPK kinase inhibitor U0126 abolished the capacity of MTII to suppress 2-h food intake and significantly decreased MTII-induced ERK phosphorylation in the NTS. U 0126 50-55 mitogen activated protein kinase 3 Rattus norvegicus 28-32 16129978-8 2005 Preconditioning protection was eliminated by the mitogen-activated extracellular kinase inhibitor U0126, which prevented phosphorylation of p44 during preconditioning, and by calmidazolium, which antagonizes the effects of Ca2+-bound calmodulin. U 0126 98-103 mitogen activated protein kinase 3 Rattus norvegicus 140-143 15961554-7 2005 Prior administration of the MAPK kinase inhibitor U0126 abolished the capacity of MTII to suppress 2-h food intake and significantly decreased MTII-induced ERK phosphorylation in the NTS. U 0126 50-55 mitogen activated protein kinase 3 Rattus norvegicus 156-159 16006144-4 2005 Surprisingly, the MEK1 inhibitors PD 98059 and U 0126 blocked both ERK1/2 and JNK phosphorylation, indicating a novel form of balancing MAPK cascade cross-talk. U 0126 47-53 mitogen activated protein kinase 3 Rattus norvegicus 67-73 15969741-7 2005 ERK1/2 but not JNK and p38 were activated by GTS-21, and the ERK phosphorylation inhibitors PD98059 and U0126 blocked protection. U 0126 104-109 mitogen activated protein kinase 3 Rattus norvegicus 0-6 15744743-7 2005 The MAPK kinase (MEK) inhibitor U0126 (10 microM) partially blocked NMDA neuroprotection, whereas LY294002, a selective inhibitor of the PI3-K pathway, did not affect the neuroprotective activity of NMDA. U 0126 32-37 mitogen activated protein kinase 3 Rattus norvegicus 4-8 16253189-4 2005 In addition, HSC-T6 cells were preincubated for 60 min with U0126, an inhibitor of MAPK/ERK kinase, irbesartan, an AT-1 receptor blocker, N-acetylcysteine (NAC), antioxidant, angiotensin converting enzyme inhibitor (ACEI), or tumor necrosis factor alpha (TNFalpha) prior to exposure to Ang II or Aldo. U 0126 60-65 mitogen activated protein kinase 3 Rattus norvegicus 83-87 16253189-4 2005 In addition, HSC-T6 cells were preincubated for 60 min with U0126, an inhibitor of MAPK/ERK kinase, irbesartan, an AT-1 receptor blocker, N-acetylcysteine (NAC), antioxidant, angiotensin converting enzyme inhibitor (ACEI), or tumor necrosis factor alpha (TNFalpha) prior to exposure to Ang II or Aldo. U 0126 60-65 mitogen activated protein kinase 3 Rattus norvegicus 88-91 16253189-9 2005 The levels of phopho-ERK1/2 protein of the irbesartan + Ang II and U0126 + Ang II groups were significantly lower than that of the Ang II group (both P < 0.01). U 0126 67-72 mitogen activated protein kinase 3 Rattus norvegicus 21-27 16253189-11 2005 The level of phopho-ERK1/2 protein of the U0126 + Aldo group was significantly lower than that of the Aldo group (P < 0.01). U 0126 42-47 mitogen activated protein kinase 3 Rattus norvegicus 20-26 15882976-6 2005 LY294002 and U0126, pharmacological inhibitors of phosphatidylinositol 3-kinase and MEK1/2 which are upstream of Akt and ERK1/2, respectively, attenuated resveratrol-induced HO-1 expression and exhibited antioxidant effects. U 0126 13-18 mitogen activated protein kinase 3 Rattus norvegicus 121-127 15731170-5 2005 Dopamine inhibited histone H4 acetylation by 2-fold in 30 min, an effect mimicked by the MAPK kinase (MEK1) inhibitor U0126. U 0126 118-123 mitogen activated protein kinase 3 Rattus norvegicus 89-93 15569628-7 2005 FSH induced PCNA expression in a time dependent manner, with a maximum stimulation at 2 h. Similarly, StAR and steroid levels increased as FSH treatment time extended, with a maximum progesterone and StAR production at 48 h. ERK1/2 inactivation by UO126 inhibited the stimulatory effects of FSH on both PCNA and StAR expression and steroid synthesis in the GCs (p less than 0.01). U 0126 248-253 mitogen activated protein kinase 3 Rattus norvegicus 225-231 15683716-4 2005 Inhibition of the upstream ERK1,2 activator MEK1,2 with U0126 prevented IL-1beta-stimulated iNOS expression, while the p38MAPK inhibitor SB03580 potentiated iNOS expression. U 0126 56-61 mitogen activated protein kinase 3 Rattus norvegicus 27-33 15680252-6 2005 Inhibition of p42/44 MAPK by MAPK kinase (MKK1) inhibitor, 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene (U0126), potentiated apoptosis by acetaldehyde or ethanol, suggesting anti-apoptotic role of p42/44 MAPK. U 0126 59-118 mitogen activated protein kinase 3 Rattus norvegicus 14-25 15680252-6 2005 Inhibition of p42/44 MAPK by MAPK kinase (MKK1) inhibitor, 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene (U0126), potentiated apoptosis by acetaldehyde or ethanol, suggesting anti-apoptotic role of p42/44 MAPK. U 0126 59-118 mitogen activated protein kinase 3 Rattus norvegicus 21-25 15680252-6 2005 Inhibition of p42/44 MAPK by MAPK kinase (MKK1) inhibitor, 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene (U0126), potentiated apoptosis by acetaldehyde or ethanol, suggesting anti-apoptotic role of p42/44 MAPK. U 0126 59-118 mitogen activated protein kinase 3 Rattus norvegicus 212-223 15680252-6 2005 Inhibition of p42/44 MAPK by MAPK kinase (MKK1) inhibitor, 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene (U0126), potentiated apoptosis by acetaldehyde or ethanol, suggesting anti-apoptotic role of p42/44 MAPK. U 0126 120-125 mitogen activated protein kinase 3 Rattus norvegicus 14-25 15680252-6 2005 Inhibition of p42/44 MAPK by MAPK kinase (MKK1) inhibitor, 1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene (U0126), potentiated apoptosis by acetaldehyde or ethanol, suggesting anti-apoptotic role of p42/44 MAPK. U 0126 120-125 mitogen activated protein kinase 3 Rattus norvegicus 21-25 15589965-4 2005 A specific inhibitor for ERK1/2 activation, U0126, inhibited phenylephrine- and U46619-induced contraction, shifting both concentration-response curves rightward. U 0126 44-49 mitogen activated protein kinase 3 Rattus norvegicus 25-31 15589965-6 2005 Both phenylephrine and U46619 induced a transient activation of ERK1/2 which was abolished by U0126 but unaffected by a general tyrosine kinase inhibitor genistein or Rho kinase inhibitor Y27632 at concentrations inhibiting more than 50% force. U 0126 94-99 mitogen activated protein kinase 3 Rattus norvegicus 64-70 15328027-8 2004 With U0126, an inhibitor of ERK activation, BrdU labeling was strikingly reduced implicating ERKs in the proliferation response. U 0126 5-10 mitogen activated protein kinase 3 Rattus norvegicus 93-97 15917991-7 2005 Interestingly, U0126 and PD98059, which inhibit activation of extracellular signal-regulated kinases 1/2 (ERK 1/2), significantly inhibited MCP-1-activated ROS generation. U 0126 15-20 mitogen activated protein kinase 3 Rattus norvegicus 62-104 15917991-7 2005 Interestingly, U0126 and PD98059, which inhibit activation of extracellular signal-regulated kinases 1/2 (ERK 1/2), significantly inhibited MCP-1-activated ROS generation. U 0126 15-20 mitogen activated protein kinase 3 Rattus norvegicus 106-113 15784961-5 2005 A selective MAPK kinase inhibitor, U0126, blocked the H2O2-induced phosphorylation of Erk1/2 (extracellular signal-regulated kinase) in PC12 cells and increased the levels of active caspase-3 in M-M17-26 under serum withdrawal or H2O2 treatment. U 0126 35-40 mitogen activated protein kinase 3 Rattus norvegicus 12-16 15784961-5 2005 A selective MAPK kinase inhibitor, U0126, blocked the H2O2-induced phosphorylation of Erk1/2 (extracellular signal-regulated kinase) in PC12 cells and increased the levels of active caspase-3 in M-M17-26 under serum withdrawal or H2O2 treatment. U 0126 35-40 mitogen activated protein kinase 3 Rattus norvegicus 86-92 15917991-9 2005 ERK 1/2 activation was increased for at least 30 min in cells incubated with MCP-1, and this effect was abolished by U0126 or DPI pretreatment. U 0126 117-122 mitogen activated protein kinase 3 Rattus norvegicus 0-7 15631696-5 2004 Hypoxia-induced cell death was increased by treatment with ERK1/2 inhibitor U0126 (10 microM), but attenuated by p38 MAPK inhibitor SB202190 (10 microM). U 0126 76-81 mitogen activated protein kinase 3 Rattus norvegicus 59-65 15341531-4 2004 In accordance with these findings, IL-1beta stimulated phosphorylation of p42/p44 MAPK, p38, and c-Jun N-terminal kinase (JNK), which was attenuated by U0126, SB202190, or SP600125, respectively. U 0126 152-157 mitogen activated protein kinase 3 Rattus norvegicus 78-86 15237095-7 2004 Incubation with the MEK/ERK inhibitors U0126 and SB386023 diminished the contractile response to S6c. U 0126 39-44 mitogen activated protein kinase 3 Rattus norvegicus 24-27 15296479-14 2004 The positive effect of ghrelin and desoctanoyl ghrelin on [(3)H]thymidine incorporation was abolished by the MAPK kinase inhibitor U0126, the PKC inhibitor GF109203X and the tyrosine kinase inhibitor tyrphostin 23, suggesting that the ghrelin-induced cell proliferation of GH3 cells is mediated both via a PKC-MAPK-dependent pathway and via a tyrosine kinase-dependent pathway. U 0126 131-136 mitogen activated protein kinase 3 Rattus norvegicus 109-113 15361284-9 2004 Inhibition of ERK1/2 by U0126 resulted in an increase of CT-1-induced tyrosine phosphorylation of STAT3 and, consequently, the protein-to-DNA ratio and [(3)H]-leucine incorporation. U 0126 24-29 mitogen activated protein kinase 3 Rattus norvegicus 14-20 15212964-5 2004 When cultured astrocytes were incubated during 8 h simulated ischemia with [1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene] (U0126), an extracellular regulated kinase 1 and 2 (Erk1/2) inhibitor or wortmannin, a phosphatidylinositol 3-kinase (PI3 kinase)/Akt inhibitor, the cell apoptosis was accelerated. U 0126 138-143 mitogen activated protein kinase 3 Rattus norvegicus 189-195 15141098-6 2004 Furthermore, the ROS formation was inhibited by the Erk1/2 pathway inhibitor U0126. U 0126 77-82 mitogen activated protein kinase 3 Rattus norvegicus 52-58 15145928-7 2004 Specific inhibitors, UO126 for ERK1/2 and SP600125 for JNK, abrogated Mip expression in response to FGF-2 in the explants. U 0126 21-26 mitogen activated protein kinase 3 Rattus norvegicus 31-37 15030400-7 2004 Inhibition of hypoxia-induced ERK1/2 pathway with intracerebral administration of U0126 significantly attenuated the neuroprotection afforded by HP against HI injury. U 0126 82-87 mitogen activated protein kinase 3 Rattus norvegicus 30-36 15016079-8 2004 The ERK1/2 phosphorylation induced by these agents was also sensitive to the MAPK kinase 1 (MEK1) inhibitor PD98059 and the MEK1/2 inhibitor U0126. U 0126 141-146 mitogen activated protein kinase 3 Rattus norvegicus 4-10 15056710-5 2004 Unexpectedly, two MEK (MAP kinase kinase) inhibitors (PD 98059 and U 0126) enhanced dendritic growth, and a ligand, basic FGF, that activates the ERK pathway inhibited the growth of these processes. U 0126 67-73 mitogen activated protein kinase 3 Rattus norvegicus 146-149 14766220-5 2004 U0126 inhibited TH promoter activity at the same concentration as it acted on ERK1/2 phosphorylation. U 0126 0-5 mitogen activated protein kinase 3 Rattus norvegicus 78-84 12868493-4 2003 U0126, an ERK1/2 kinase inhibitor, inhibited both the production of O2- and the translocation of p47(phox) elicited by fMLP. U 0126 0-5 mitogen activated protein kinase 3 Rattus norvegicus 10-16 14602717-7 2004 Inhibition of the MEK1,2/ERK1,2 pathway by either serum starvation or treatment with selective MEK1,2 inhibitors PD98059 and U0126 or expression of a dominant-negative mutant form of MEK1 decreased the amplitude of the G17-stimulated Ca2+ release response. U 0126 125-130 mitogen activated protein kinase 3 Rattus norvegicus 25-31 12882762-7 2003 Blocking ERK1/2 activation by MEK1/2 inhibitors (PD-98059 or U-0126) diminishes HB-EGF-induced Fra-1 accumulation and subsequent downregulation of elastin mRNA. U 0126 61-67 mitogen activated protein kinase 3 Rattus norvegicus 9-15 12951049-9 2003 The activation of AKT, p70(s6k), and ERK1/2 induced by HGF was abolished by pre-treatment with LY294002, a phosphoinositide 3-OH kinase (PI3K) inhibitor, and U0126, a mitogen-activated protein kinase/ERK kinase (MEK) inhibitor, respectively. U 0126 158-163 mitogen activated protein kinase 3 Rattus norvegicus 37-43 12929934-11 2003 PTH activated p42/p44 MAP kinase, and the effects of PTH, PDBu, and ionomycin on PLD, but not on calcium influx, were prevented by the MEK inhibitors PD98059 and U0126. U 0126 162-167 mitogen activated protein kinase 3 Rattus norvegicus 18-21 12736249-5 2003 We observed that growth stimulation was associated with stimulation of ERK1/2 phosphorylation (ERK-P), and both growth and ERK-P could be blocked by the MEK inhibitor (U0126, 100 nm). U 0126 168-173 mitogen activated protein kinase 3 Rattus norvegicus 71-77 12860392-1 2003 Exposure of PC12 cells to 100 microM peroxynitrite promotes phosphorylation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) sensitive to PD98059 or U0126. U 0126 159-164 mitogen activated protein kinase 3 Rattus norvegicus 79-125 12860392-1 2003 Exposure of PC12 cells to 100 microM peroxynitrite promotes phosphorylation of extracellular signal-regulated kinases 1 and 2 (ERK1/2) sensitive to PD98059 or U0126. U 0126 159-164 mitogen activated protein kinase 3 Rattus norvegicus 127-133 12860392-2 2003 At higher concentrations, however, ERK1/2 phosphorylation was prevented by U0126 and increased by PD98059 via a U0126-sensitive mechanism. U 0126 75-80 mitogen activated protein kinase 3 Rattus norvegicus 35-41 12860392-2 2003 At higher concentrations, however, ERK1/2 phosphorylation was prevented by U0126 and increased by PD98059 via a U0126-sensitive mechanism. U 0126 112-117 mitogen activated protein kinase 3 Rattus norvegicus 35-41 12832521-4 2003 The effects of the estrogens were specific to the ERK1/2 MAPK pathway and were blocked by U0126, an inhibitor of the ERK1/2 MAPK kinase (MEK1/2). U 0126 90-95 mitogen activated protein kinase 3 Rattus norvegicus 50-56 12832521-4 2003 The effects of the estrogens were specific to the ERK1/2 MAPK pathway and were blocked by U0126, an inhibitor of the ERK1/2 MAPK kinase (MEK1/2). U 0126 90-95 mitogen activated protein kinase 3 Rattus norvegicus 57-61 12832521-4 2003 The effects of the estrogens were specific to the ERK1/2 MAPK pathway and were blocked by U0126, an inhibitor of the ERK1/2 MAPK kinase (MEK1/2). U 0126 90-95 mitogen activated protein kinase 3 Rattus norvegicus 117-123 23604762-6 2003 U0126 (25 microM) completely abolished ERK1/2 activation induced by OTA. U 0126 0-5 mitogen activated protein kinase 3 Rattus norvegicus 39-45 12535662-6 2003 PD98059 and U-0126, inhibitors of the upstream kinase that activates p44/p42 MAP kinase, significantly reduced the simvastatin-induced VEGF release in a dose-dependent manner. U 0126 12-18 mitogen activated protein kinase 3 Rattus norvegicus 69-72 12535662-7 2003 The phosphorylation of p44/p42 MAP kinase induced by simvastatin was reduced by PD98059 or U-0126. U 0126 91-97 mitogen activated protein kinase 3 Rattus norvegicus 23-26 12466948-10 2002 The effect of U0126 on the percentage of pyruvate dehydrogenase in the active form suggests that the ERK1/2 pathway may also be involved in regulation of the phosphorylation state of this enzyme. U 0126 14-19 mitogen activated protein kinase 3 Rattus norvegicus 101-107 12370536-9 2002 The phosphorylation of pancreatic ERK1/2 was attenuated in PD98059- and U0126-treated animals at both 30 minutes and 3 hours after cerulein injection. U 0126 72-77 mitogen activated protein kinase 3 Rattus norvegicus 34-40 12370536-10 2002 Rats rendered neutropenic with vinblastine and pretreated with U0126 still showed attenuated manifestations of cerulein-induced acute pancreatitis, a finding suggesting that pancreatic ERK1/2 is mostly responsible for the effect, rather than infiltrating neutrophils. U 0126 63-68 mitogen activated protein kinase 3 Rattus norvegicus 185-191 12110546-10 2002 Inhibition of mitogen-activated protein (MAP)/ERK kinase (MEK)1/2 by U0126 (a specific MEK1/2 inhibitor) reduced shear-induced ERK1/2 phosphorylation and cell proliferation. U 0126 69-74 mitogen activated protein kinase 3 Rattus norvegicus 127-133 11839529-2 2002 To determine if ERK-1/2 signaling plays a role in fetal lung branching morphogenesis, U-0126, an inhibitor of the upstream kinase MAP ERK kinase (MEK), was added to fetal lung explants in vitro. U 0126 86-92 mitogen activated protein kinase 3 Rattus norvegicus 16-23 12079690-7 2002 The angiotensin II- and endothelin-1-induced phosphorylations of p44/42 MAP kinases were inhibited by PD98059 as well as U0126 in the intact aorta. U 0126 121-126 mitogen activated protein kinase 3 Rattus norvegicus 65-68 11782488-10 2002 Finally, pretreatment of cells with PD98059 and U0126 resulted in an increase in cell death including apoptosis by H(2)O(2) in ERK1/2 down-regulated cells as well as in intact PC12 cells. U 0126 48-53 mitogen activated protein kinase 3 Rattus norvegicus 127-133 11839529-4 2002 At the same time, U-0126 treatment reduced ERK-1/2, slightly increased p38 kinase, but did not change c-Jun NH(2)-terminal kinase activities, indicating that U-0126 specifically inhibited the ERK-1/2 enzymes. U 0126 18-24 mitogen activated protein kinase 3 Rattus norvegicus 192-199 11839529-4 2002 At the same time, U-0126 treatment reduced ERK-1/2, slightly increased p38 kinase, but did not change c-Jun NH(2)-terminal kinase activities, indicating that U-0126 specifically inhibited the ERK-1/2 enzymes. U 0126 158-164 mitogen activated protein kinase 3 Rattus norvegicus 192-199 11839529-7 2002 Thus U-0126 causes specific inhibition of ERK-1/2 signaling, diminished branching morphogenesis, characterized by increased mesenchymal apoptosis, and decreased epithelial proliferation in fetal lung explants. U 0126 5-11 mitogen activated protein kinase 3 Rattus norvegicus 42-49 11884280-4 2002 The MAPK kinase inhibitor (MEKI), U0126 (1 micromol/L), blocked ERK1/2 phosphorylation and at higher doses (5 micromol/L) blocked BMK1 phosphorylation. U 0126 34-39 mitogen activated protein kinase 3 Rattus norvegicus 4-8 11884280-4 2002 The MAPK kinase inhibitor (MEKI), U0126 (1 micromol/L), blocked ERK1/2 phosphorylation and at higher doses (5 micromol/L) blocked BMK1 phosphorylation. U 0126 34-39 mitogen activated protein kinase 3 Rattus norvegicus 64-70 11839529-4 2002 At the same time, U-0126 treatment reduced ERK-1/2, slightly increased p38 kinase, but did not change c-Jun NH(2)-terminal kinase activities, indicating that U-0126 specifically inhibited the ERK-1/2 enzymes. U 0126 18-24 mitogen activated protein kinase 3 Rattus norvegicus 43-50 11846418-6 2002 Insulin (1 nM)-stimulated NOS activity was also abolished by U0126, an inhibitor of p42/p44 MAPK activation, and by 1 microM okadaic acid (OA), which inhibits both PP-1 and PP-2A but not by 1 nM OA which inhibits only PP-2A. U 0126 61-66 mitogen activated protein kinase 3 Rattus norvegicus 88-91 11145995-4 2001 The glutamate-induced ERK1/2 phosphorylation was blocked by U0126 and PD98059, specific inhibitors of the MAPK-activating enzyme MEK. U 0126 60-65 mitogen activated protein kinase 3 Rattus norvegicus 22-28 11735115-4 2001 Using primary rat GCs from early antral follicles cultured in serum-free medium for 48 h, we found that the addition of a specific inhibitor of ERK1/2 activation, U0126, caused the attenuation or enhancement of FSH-induced progesterone or estradiol production, respectively, in a dose-dependent manner. U 0126 163-168 mitogen activated protein kinase 3 Rattus norvegicus 144-150 11393781-6 2001 Activation of ERK-1 and the phosphorylation of ER-alpha, by both estrogen and strain, were prevented by the MAP kinase kinase (MEK) inhibitor U0126 and the protein kinase A (PKA) inhibitor (PKI). U 0126 142-147 mitogen activated protein kinase 3 Rattus norvegicus 14-19 11312036-9 2001 Treatment of cells with U0126 [1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene] an ERK1/2 inhibitor or SB203580 [4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-5-(4-pyridyl)1H-imidazole] a p38 kinase inhibitor effectively prevented SAAD-potentiated arsenic toxicity. U 0126 24-29 mitogen activated protein kinase 3 Rattus norvegicus 95-101 11137625-4 2001 The phosphorylation of p44/42 MAPK occurred rapidly within 5 min after addition of bFGF, and lasted for 48 h. The bFGF-induced phosphorylation of p44/42 MAPK and axonal branch formation were both blocked by simultaneous addition of U0126 and PD98059, specific inhibitors of MAPK kinases. U 0126 232-237 mitogen activated protein kinase 3 Rattus norvegicus 23-26 11137625-4 2001 The phosphorylation of p44/42 MAPK occurred rapidly within 5 min after addition of bFGF, and lasted for 48 h. The bFGF-induced phosphorylation of p44/42 MAPK and axonal branch formation were both blocked by simultaneous addition of U0126 and PD98059, specific inhibitors of MAPK kinases. U 0126 232-237 mitogen activated protein kinase 3 Rattus norvegicus 146-149 11137625-5 2001 Furthermore, when U0126 and PD98059 were added 24 h after bFGF, phosphorylation of p44/42 m MAPK was decreased, and axonal branch formation was stopped. U 0126 18-23 mitogen activated protein kinase 3 Rattus norvegicus 83-86 11171084-5 2001 Moreover, the induction of HB-EGF mRNA was blocked by PD098059 and U0126, inhibitors that prevent the activation of p42/p44 MAPKs and extracellular signal-regulated protein kinase 5 (ERK5). U 0126 67-72 mitogen activated protein kinase 3 Rattus norvegicus 120-123 34010584-11 2021 U0126, the inhibitor of ERK1/2 pathway, reversed the protective effects of myrtenol on brain tissue damage and angiogenesis in MCAO rats. U 0126 0-5 mitogen activated protein kinase 3 Rattus norvegicus 24-30 10713403-4 2000 EGF-induced ERK1/2 phosphorylation and promotion of neuronal survival were both blocked by U0126 and PD98059, inhibitors of the MAPK-activating enzyme MEK. U 0126 91-96 mitogen activated protein kinase 3 Rattus norvegicus 12-18 34971676-11 2022 Both extracellular signal-related kinase 1 and 2 (ERK1/2) inhibitors (U0126) and P38 inhibitors (SB203580) significantly inhibited HG-increased VSMC ETB receptors. U 0126 70-75 mitogen activated protein kinase 3 Rattus norvegicus 50-56 34562585-10 2021 But the effect of LV-siDUSP1 can be reversed by the treatment with ERK1/2 pathway inhibitor U0126. U 0126 92-97 mitogen activated protein kinase 3 Rattus norvegicus 67-73 34428599-8 2021 However, the levels of phosphorylated Cx43 decreased after pre-treatment with candesartan (AT1 receptor blocker), GF109203X (protein kinase C (PKC) blocker) and U0126 (mitogen-activated protein kinases/extracellular signal-regulated kinase1/2(MEK/ERK1/2)-specific blocker) in AngII-stimulated A7r5 cells. U 0126 161-166 mitogen activated protein kinase 3 Rattus norvegicus 247-253 34607570-12 2021 Furthermore, inhibition of ERK1/2 using U0126 abolished the anti-arrhythmic action of empagliflozin and ERK1/2 phosphorylation. U 0126 40-45 mitogen activated protein kinase 3 Rattus norvegicus 27-33 34607570-12 2021 Furthermore, inhibition of ERK1/2 using U0126 abolished the anti-arrhythmic action of empagliflozin and ERK1/2 phosphorylation. U 0126 40-45 mitogen activated protein kinase 3 Rattus norvegicus 104-110 34797522-6 2022 While intra-SC administration of U0126 (inhibitor of ERK 1/2 and long-term memory) impaired memory formation, lidocaine (local anaesthetic) hindered memory recall. U 0126 33-38 mitogen activated protein kinase 3 Rattus norvegicus 53-60 34434266-11 2021 The results indicated that compared with the control group, IL-17F increased the protein expression of phosphorylated-ERK1/2, Runx2 and Osterix, whereas U0126 reversed IL-17F-mediated effects. U 0126 153-158 mitogen activated protein kinase 3 Rattus norvegicus 118-124 35091962-6 2022 Further study suggested that the protective role of GSK-126 in ischemic rats was antagonized by U0126, an inhibitor of ERK1/2. U 0126 96-101 mitogen activated protein kinase 3 Rattus norvegicus 119-125 34594239-10 2021 The effect of T4 in endothelium-denuded arteries was abolished by inhibiting ERK1/2 activation with U0126 as well as by ILK inhibitor Cpd22 but persisted in the presence of Src- or Rho-kinase inhibitors (PP2 and Y27632, respectively). U 0126 100-105 mitogen activated protein kinase 3 Rattus norvegicus 77-83 34572303-8 2021 Aldosterone enhanced ERK1/2 phosphorylation and inhibition of ERK1/2-phosphorylation (10 micromol/L U0126) prevented aldosterone-induced alkalinization. U 0126 100-105 mitogen activated protein kinase 3 Rattus norvegicus 62-68 35574901-10 2022 The ERK1/2 inhibitor (U0126) and PI3K inhibitor (LY294002) significantly reduced LIPUS-induced phosphorylation of ERK1/2 and PI3K-Akt, respectively, which in turn reduced the LIPUS-induced viability of H9C2s in 3D bio-printed cell-laden GelMA scaffolds. U 0126 22-27 mitogen activated protein kinase 3 Rattus norvegicus 4-10 35574901-10 2022 The ERK1/2 inhibitor (U0126) and PI3K inhibitor (LY294002) significantly reduced LIPUS-induced phosphorylation of ERK1/2 and PI3K-Akt, respectively, which in turn reduced the LIPUS-induced viability of H9C2s in 3D bio-printed cell-laden GelMA scaffolds. U 0126 22-27 mitogen activated protein kinase 3 Rattus norvegicus 114-120 33637715-8 2021 In addition, the CnA inhibitor cyclosporin A and p-ERK1/2 inhibitor U0126 improved HG-induced cardiomyocyte hypertrophy by promoting and inhibiting phosphorylation of Drp1 at S637 and S616, respectively. U 0126 68-73 mitogen activated protein kinase 3 Rattus norvegicus 51-57 35159398-5 2022 Also, we report here that decreased OXPHOS activity following ERK1/2 inhibition (U0126 treatment) during IgE-Ag activation was mediated by the dephosphorylation of Serine 73 mitochondrial MITF, which inhibited its association with PDH. U 0126 81-86 mitogen activated protein kinase 3 Rattus norvegicus 62-68 35112334-9 2022 What"s more, ERK1/2 signaling pathway inhibitor U0126 also could inhibit the expression of VEGF. U 0126 48-53 mitogen activated protein kinase 3 Rattus norvegicus 13-19 33707758-9 2021 The expression of p-Connexin 43 was significantly decreased in the presence of the ERK1/2 inhibitor U0126 but not the p38 inhibitor SB203580. U 0126 100-105 mitogen activated protein kinase 3 Rattus norvegicus 83-89 35053304-8 2022 U0126 pre-treatment suppressed NE-induced ERK1/2 phosphorylation but failed to attenuate hypertrophy. U 0126 0-5 mitogen activated protein kinase 3 Rattus norvegicus 42-48 35053304-9 2022 U0126 inhibition of ERK1/2 phosphorylation prevented NE-mediated upregulation of CaValpha2delta1, whereas CaVbeta3 protein levels remained elevated. U 0126 0-5 mitogen activated protein kinase 3 Rattus norvegicus 20-26 32665706-12 2021 Moreover, the ERK1/2 inhibitor U0126 (10 muM) had the similar effects as MB. U 0126 31-36 mitogen activated protein kinase 3 Rattus norvegicus 14-20 33166587-0 2021 BLOCKADE OF ERK1/2 ACTIVATION WITH U0126 OR PEP7 REDUCES SODIUM APPETITE AND ANGIOTENSIN II-INDUCED PRESSOR RESPONSES IN SPONTANEOUSLY HYPERTENSIVE RATS. U 0126 35-40 mitogen activated protein kinase 3 Rattus norvegicus 12-18 33422538-5 2021 Roscovitine (a CDK5 inhibitor) suppressed the effect of tunicamycin in the molecular layer of the dentate gyrus and the CA1 region, while U0126 (an ERK1/2 inhibitor) reversed it in the CA1 region. U 0126 138-143 mitogen activated protein kinase 3 Rattus norvegicus 148-154 33166587-6 2021 The blockade of ERK1/2 activation with icv injections of U0126 (MEK1/2 inhibitor, 2 mM; 2 mul) reduced 0.3 M NaCl induced by furosemide + captopril (5.0 +- 1.0, vs. vehicle: 7.3 +- 0.7 ml/120 min) or WD-PR (4.6 +- 1.3, vs. vehicle: 10.3 +- 1.4 ml/120 min). U 0126 57-62 mitogen activated protein kinase 3 Rattus norvegicus 16-22 32963697-9 2020 Correspondingly, both the ERK1/2 inhibitor (U0126) and pan-caspase inhibitor (Z-VAD-FMK) could at least partially abolish the ADR-associated cytotoxicity in H9c2 cells. U 0126 44-49 mitogen activated protein kinase 3 Rattus norvegicus 26-32 33247374-6 2022 In addition, we showed that the phosphorylation levels of ERK1/2, JNK, and P38 were upregulated in apoptotic hUC-MSCs, while curcumin increased the phosphorylation of ERK1/2 but did not activate JNK or P38, and these effects were reversed by the p42/44 antagonist U0126. U 0126 264-269 mitogen activated protein kinase 3 Rattus norvegicus 58-64 33247374-6 2022 In addition, we showed that the phosphorylation levels of ERK1/2, JNK, and P38 were upregulated in apoptotic hUC-MSCs, while curcumin increased the phosphorylation of ERK1/2 but did not activate JNK or P38, and these effects were reversed by the p42/44 antagonist U0126. U 0126 264-269 mitogen activated protein kinase 3 Rattus norvegicus 167-173 32794652-4 2020 U0126 (10 muM) inhibited JC105-mediated phosphorylation of ERK1/2 and DRP1 without affecting AKT or AMPK, which were also not regulated by JC105. U 0126 0-5 mitogen activated protein kinase 3 Rattus norvegicus 59-65 32407275-8 2020 Intrathecal injection of U0126 (a MEK inhibitor) blocking ERK1/2 phosphorylation blunted up-regulation of Nav1.7 in the DRG and correspondingly attenuated hyperalgesia. U 0126 25-30 mitogen activated protein kinase 3 Rattus norvegicus 58-64 32908568-13 2020 AD and the ERK1/2 inhibitor U0126 (10 mumol/L) inhibited VSMC proliferation and reduced the overexpression of miR-17~92a. U 0126 28-33 mitogen activated protein kinase 3 Rattus norvegicus 11-17 32112164-9 2020 What"s more, similar effects of ERK1/2 inhibitor U0126 with Xuefu Zhuyu decoction proved the involvement of ERK1/2 signaling pathway. U 0126 49-54 mitogen activated protein kinase 3 Rattus norvegicus 32-38 32112164-9 2020 What"s more, similar effects of ERK1/2 inhibitor U0126 with Xuefu Zhuyu decoction proved the involvement of ERK1/2 signaling pathway. U 0126 49-54 mitogen activated protein kinase 3 Rattus norvegicus 108-114 32522929-4 2020 It was interesting that U0126, an inhibitor of the activation of extracellular signal-regulated kinase 1 (ERK1), ERK2, and ERK5, inhibited the Na2S3-induced gene expression of EGR1 and KLF4. U 0126 24-29 mitogen activated protein kinase 3 Rattus norvegicus 65-104 32522929-4 2020 It was interesting that U0126, an inhibitor of the activation of extracellular signal-regulated kinase 1 (ERK1), ERK2, and ERK5, inhibited the Na2S3-induced gene expression of EGR1 and KLF4. U 0126 24-29 mitogen activated protein kinase 3 Rattus norvegicus 106-110 31905925-4 2019 We also showed that (1) the AUR-induced GDNF production was inhibited by U0126, a specific inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase (ERK) 1/2, and by H89, a specific inhibitor of protein kinase A (PKA); and (2) AUR induced the phosphorylation of cAMP response element-binding protein (CREB), a transcription factor located within the nucleus. U 0126 73-78 mitogen activated protein kinase 3 Rattus norvegicus 137-184 31795399-10 2019 Co-treatment of U0126 (an ERK1/2 inhibitor) alleviated vasogenic edema formation and the reduced dystrophin-AQP4 expressions induced by 67-kDa LR neutralization. U 0126 16-21 mitogen activated protein kinase 3 Rattus norvegicus 26-32 31468983-12 2019 FAK inhibitor (PF-573228) and ERK1/2 inhibitor (U0126) were proved, in turn, decreased the BMSCs migration induced using LIPUS (p < .05). U 0126 48-53 mitogen activated protein kinase 3 Rattus norvegicus 30-36 31218464-9 2019 The AQP9 gene knock-down or exogenous administration of the ERK1/2 inhibitor U0126 could improve the above indexes. U 0126 77-82 mitogen activated protein kinase 3 Rattus norvegicus 60-66 31306636-7 2019 Mirtazapine treatment increased phosphorylation of extracellular signal-regulated kinase (ERK) 1/2, and the mirtazapine-induced GDNF and BDNF expression were blocked by MAPK/ERK kinase (MEK) inhibitor (U0126). U 0126 202-207 mitogen activated protein kinase 3 Rattus norvegicus 51-98 31306636-7 2019 Mirtazapine treatment increased phosphorylation of extracellular signal-regulated kinase (ERK) 1/2, and the mirtazapine-induced GDNF and BDNF expression were blocked by MAPK/ERK kinase (MEK) inhibitor (U0126). U 0126 202-207 mitogen activated protein kinase 3 Rattus norvegicus 169-173 31199065-9 2019 SB203580 (p38 inhibitor) and U0126 (ERK1/2 inhibitor) significantly decreased PM2.5 -induced elevated contraction and mRNA and protein expression of 5-HT2A receptor. U 0126 29-34 mitogen activated protein kinase 3 Rattus norvegicus 36-42 31199065-13 2019 SB203580 and U0126 inhibited the PM2.5 caused increased phosphorylation protein of p38 and ERK1/2. U 0126 13-18 mitogen activated protein kinase 3 Rattus norvegicus 91-97 31880530-10 2019 In in vivo trial, it was found that the protein expression level of p-ERK1/2 in cerebral tissue in the MCAO group was significantly increased, when compared with that of the sham-operated group, while the protein expression level of p-Erk1/2 in the U0126 group was significantly lower than that in the MCAO group. U 0126 249-254 mitogen activated protein kinase 3 Rattus norvegicus 235-241 31187398-8 2019 In cultured hypoxic hippocampal neurons, individual blockage of MAPK signaling by the MEK1/2 inhibitor (U0126), but not by the P38 inhibitor (SB203580) or JNK inhibitor (SP600125), completely prevented the upregulation of all three kinds of SK channels. U 0126 104-109 mitogen activated protein kinase 3 Rattus norvegicus 64-68 31387634-10 2019 p-JNK was not significantly decreased in SP600125 + DBP group, while p-ERK1/2 was significantly decreased in U0126 + DBP group. U 0126 109-114 mitogen activated protein kinase 3 Rattus norvegicus 71-77 31360172-10 2019 The increase in ALP, mineral deposition, and osteoblastic genes induced by the mechanical stretch-EPO combination was inhibited by U0126, an ERK1/2 inhibitor. U 0126 131-136 mitogen activated protein kinase 3 Rattus norvegicus 141-147 31373312-8 2019 In cultured primary renal tubular epithelial cells (TECs), administration of saturated fatty acid palmitate resulted in an upregulation of KIM-1, osteopontin, and CD44, which was greatly attenuated by U0126, an inhibitor of extracellular signal-regulated kinase (ERK)1/2. U 0126 201-206 mitogen activated protein kinase 3 Rattus norvegicus 224-270 30648910-0 2019 Blockade of ERK1/2 by U0126 alleviates uric acid-induced EMT and tubular cell injury in rats with hyperuricemic nephropathy. U 0126 22-27 mitogen activated protein kinase 3 Rattus norvegicus 12-18 29889817-8 2019 Treatment with U0126 (a specific ERK1/2 inhibitor) reversed the effects of PE on IkappaBalpha, p38MAPK and JNK phosphorylation as well as caspase-3/-8/-9 activation in LPS-treated ARVMs. U 0126 15-20 mitogen activated protein kinase 3 Rattus norvegicus 33-39 31118889-6 2019 U0126 (an ERK1/2 inhibitor) elongated mitochondrial length, accompanied by the reduced DRP1-S616 phosphorylation. U 0126 0-5 mitogen activated protein kinase 3 Rattus norvegicus 10-16 31005550-7 2019 KEY FINDINGS: U-0126 administration reversed the neuroprotective effect induced by zeranol through decreasing ratio of p-ERK1/2:ERK1/2 and Bcl-2/Bax in brain tissue. U 0126 14-20 mitogen activated protein kinase 3 Rattus norvegicus 121-127 31005550-7 2019 KEY FINDINGS: U-0126 administration reversed the neuroprotective effect induced by zeranol through decreasing ratio of p-ERK1/2:ERK1/2 and Bcl-2/Bax in brain tissue. U 0126 14-20 mitogen activated protein kinase 3 Rattus norvegicus 128-134 31200778-10 2019 However, the abovementioned NE-induced changes could be suppressed by the specific ERK-1/2 inhibitor U0126. U 0126 101-106 mitogen activated protein kinase 3 Rattus norvegicus 83-90 30362534-9 2019 Albumin-induced CD44 and claudin-1 expression were greatly suppressed in the presence of the ERK1/2 inhibitor, U0126. U 0126 111-116 mitogen activated protein kinase 3 Rattus norvegicus 93-99 30648910-6 2019 Administration of U0126, a selective inhibitor of ERK1/2, blocked all these responses. U 0126 18-23 mitogen activated protein kinase 3 Rattus norvegicus 50-56 30132884-7 2019 Inactivation of ERK1/2 and p38 MAPK pathways using selective inhibitors (U0126 and SB203580) abrogated PXR-induced SMC proliferation and migration. U 0126 73-78 mitogen activated protein kinase 3 Rattus norvegicus 16-22 30439349-5 2019 MEK/ERK1/2 inhibitor U0126 was administered at 0, 6, and 24 h following reperfusion and the functional properties of the ophthalmic artery were evaluated at 48 h post reperfusion. U 0126 21-26 mitogen activated protein kinase 3 Rattus norvegicus 4-10 30639310-11 2019 The NH4Cl-induced alterations were reversed by reactive oxygen species scavenger N-acetylcysteine and ERK1/2 inhibitor U0126. U 0126 119-124 mitogen activated protein kinase 3 Rattus norvegicus 102-108 30700692-7 2019 Our results also indicated that there was significantly lower expression of D1R, p-ERK1/2, and c-Fos in the IC of the U0126+Ket group, SCH23390+Ket group, and Ket+EA1 group as compared with that of the Ket group. U 0126 118-123 mitogen activated protein kinase 3 Rattus norvegicus 83-89 30241394-6 2018 SC increased the levels of p-ERK1/2 and p-c-Fos, which were inhibited by U0126. U 0126 73-78 mitogen activated protein kinase 3 Rattus norvegicus 29-35 31237214-10 2019 Nevertheless, U0126 (an inhibitor of MEK1/2) pre-treatment reduced the p-ERK1/2 level in both the tGCI+ U0126 group and the tGCI+ U0126+ NaHS group. U 0126 14-19 mitogen activated protein kinase 3 Rattus norvegicus 73-79 30085340-7 2018 Meanwhile, the NF-kappabeta p65 inhibitor ammonium pyrrolidinedithiocarbamate and the ERK1/2 inhibitor U0126, but not the p38 inhibitor SB203580, were able to block oxLDL/beta2GPI/anti-beta2GPI complex-induced foam cell formation and migration in A7r5 cells. U 0126 103-108 mitogen activated protein kinase 3 Rattus norvegicus 86-92 30606985-5 2019 Furthermore, the increases in norgalanthamine-induced ERK 1/2 activation and subsequent DPC proliferation were suppressed by the mitogen-activated protein kinase/ERK kinase (MEK) 1/2 inhibitor, U0126. U 0126 194-199 mitogen activated protein kinase 3 Rattus norvegicus 54-61 30367147-7 2018 This protection required ERK1/2 activity as it was prevented by inhibitors PD98059 and U0126. U 0126 87-92 mitogen activated protein kinase 3 Rattus norvegicus 25-31 29567110-8 2018 Furthermore, Ni-inhibited testosterone synthetase expression levels and testosterone secretion were all alleviated by co-treatment with MAPK specific inhibitors (U0126 and SB203580, respectively), implying that Ni inhibited testosterone synthesis through activating ERK1/2 and p38 MAPK signal pathways in Leydig cells. U 0126 162-167 mitogen activated protein kinase 3 Rattus norvegicus 136-140 29567110-8 2018 Furthermore, Ni-inhibited testosterone synthetase expression levels and testosterone secretion were all alleviated by co-treatment with MAPK specific inhibitors (U0126 and SB203580, respectively), implying that Ni inhibited testosterone synthesis through activating ERK1/2 and p38 MAPK signal pathways in Leydig cells. U 0126 162-167 mitogen activated protein kinase 3 Rattus norvegicus 266-272 29567110-8 2018 Furthermore, Ni-inhibited testosterone synthetase expression levels and testosterone secretion were all alleviated by co-treatment with MAPK specific inhibitors (U0126 and SB203580, respectively), implying that Ni inhibited testosterone synthesis through activating ERK1/2 and p38 MAPK signal pathways in Leydig cells. U 0126 162-167 mitogen activated protein kinase 3 Rattus norvegicus 281-285 29369532-2 2018 The aim of this study was to investigate whether or not the MEK/ERK1/2 pathway is involved in the observed upregulation and whether specific MEK/ERK1/2 inhibitors U0126 and trametinib can prevent it. U 0126 163-168 mitogen activated protein kinase 3 Rattus norvegicus 145-151 29536419-12 2018 The U0126 (MEK/ERK1/2 inhibitor) and SB203580 (p38 inhibitor) significantly attenuated both organ cultured-induced and PM2.5-induced up-regulation of ETB receptor. U 0126 4-9 mitogen activated protein kinase 3 Rattus norvegicus 15-21 29642540-7 2018 On the other hand, both of an ERK inhibitor U0126 (non-specific specific inhibitor) and SCH772984 (specific inhibitor) attenuated the enhanced cell growth by sericin, and the growth level in the case of co-treatment with sericin and ERK1/2 inhibitor was similar to that of cells treated with ERK1/2 inhibitor alone. U 0126 44-49 mitogen activated protein kinase 3 Rattus norvegicus 233-239 29425910-9 2018 However, these benefits were diminished when the MEK1/2/ERK1/2/p90RSK pathway was inhibited by U0126. U 0126 95-100 mitogen activated protein kinase 3 Rattus norvegicus 56-62 29425910-10 2018 We also found that TXL upregulated the expression levels of p-MEK1/2, p-ERK1/2, p-p90RSK and p-bad, which were all significantly reversed by U0126. U 0126 141-146 mitogen activated protein kinase 3 Rattus norvegicus 72-78 29642540-7 2018 On the other hand, both of an ERK inhibitor U0126 (non-specific specific inhibitor) and SCH772984 (specific inhibitor) attenuated the enhanced cell growth by sericin, and the growth level in the case of co-treatment with sericin and ERK1/2 inhibitor was similar to that of cells treated with ERK1/2 inhibitor alone. U 0126 44-49 mitogen activated protein kinase 3 Rattus norvegicus 292-298 28959190-7 2017 Additionally, pharmacological results demonstrated that the application of the ERK1/2 activation inhibitor U0126 into the PPT prevented RSHD and suppressed BDNF expression in the PPT. U 0126 107-112 mitogen activated protein kinase 3 Rattus norvegicus 79-85 29278848-6 2018 Furthermore, pretreatment of ERK1/2 inhibitor U0126 or p38 inhibitor SB203580 entirely eliminated BPA-induced increases in the densities of the dendritic spine and synapse. U 0126 46-51 mitogen activated protein kinase 3 Rattus norvegicus 29-35 29091876-7 2018 The ERK1/2 inhibitor U0126 enhanced the inhibitory effects of CTRP6 overexpression on cell proliferation, migration and ECM expression in TGF-beta1-stimulated NRK-49F cells. U 0126 21-26 mitogen activated protein kinase 3 Rattus norvegicus 4-10 29950141-10 2018 Results also showed that inhibition of ERK1/2 pathway using U0126 significantly inhibited TNF-alpha-induced autophagy. U 0126 60-65 mitogen activated protein kinase 3 Rattus norvegicus 39-45 28762104-9 2017 Co-treatment with the PI3K inhibitor LY294002 or ERK1/2 inhibitor U0126 significantly reverses the protective role of NGF on HG-induced excessive ER stress and subsequent apoptosis. U 0126 66-71 mitogen activated protein kinase 3 Rattus norvegicus 49-55 29473447-0 2018 U0126 protects hippocampal CA1 neurons against forebrain ischemia-induced apoptosis via the ERK1/2 signaling pathway and NMDA receptors. U 0126 0-5 mitogen activated protein kinase 3 Rattus norvegicus 92-98 29473447-9 2018 Blocking the ERK1/2 signaling pathway by administration U0126 attenuated apoptotic neuronal cell death via inhibition of NMDA receptors. U 0126 56-61 mitogen activated protein kinase 3 Rattus norvegicus 13-19 29543778-9 2018 The inhibition of NMDA toxicity by BL-M was dramatically reversed by U0126, a well-known MEK inhibitor, suggesting that ERK1/2-mediated CREB phosphorylation is required for the neuroprotective action. U 0126 69-74 mitogen activated protein kinase 3 Rattus norvegicus 120-126 28805677-8 2017 In contrast, administration of rat serum albumin (RSA, 0.1-0.5 mg/mL) resulted in a dose-dependent increase in MMP-9 expression and secretion by TECs, which was abolished in the presence of an ERK1/2-specific inhibitor, U0126. U 0126 220-225 mitogen activated protein kinase 3 Rattus norvegicus 193-199 28601633-8 2017 U0126 (an ERK1/2 inhibitor) co-treatment abolished the protective effect of LMB on SE-induced neuronal death without alterations in PKA and PP2B phosphorylations. U 0126 0-5 mitogen activated protein kinase 3 Rattus norvegicus 10-16 28451751-6 2017 The effect of CNP on P-ERK1/2 was sensitive to pharmacological blockade of MEK (U0126) and Src kinases (PP2). U 0126 80-85 mitogen activated protein kinase 3 Rattus norvegicus 23-29 28798340-6 2017 Intra-IL infusion of BDNF antibody and the ERK1/2 inhibitor U0126 reversed PCMS-induced enhancement of fear extinction. U 0126 60-65 mitogen activated protein kinase 3 Rattus norvegicus 43-49 28272757-7 2017 The involvement of ERK1/2 in the activation of STAT3 was evidenced by the capacity of the MEK inhibitor U0126 to prevent Ald-mediated ERK1/2 and STAT3 phosphorylation. U 0126 104-109 mitogen activated protein kinase 3 Rattus norvegicus 19-25 28506883-9 2017 Finally, a downstream step, MEK1/2-ERK1/2 was also investigated, and, similar to Src inhibition, the MEK1/2 inhibitor (U0126) suppressed the BUF effect. U 0126 119-124 mitogen activated protein kinase 3 Rattus norvegicus 35-41 28272757-7 2017 The involvement of ERK1/2 in the activation of STAT3 was evidenced by the capacity of the MEK inhibitor U0126 to prevent Ald-mediated ERK1/2 and STAT3 phosphorylation. U 0126 104-109 mitogen activated protein kinase 3 Rattus norvegicus 134-140 28479396-7 2017 Similar to TRPC6 knockdown, ERK1/2 inhibition by U0126 evoked mitochondrial elongation with diminished DRP1-S616 phosphorylation, and facilitated SE-induced DGC degeneration independent of seizure severity. U 0126 49-54 mitogen activated protein kinase 3 Rattus norvegicus 28-34 28469203-3 2017 In normal retinas, intravitreal injection of BaCl2 significantly increased GFAP expression in Muller cells, which was eliminated by co-injecting mitogen-activated protein kinase (MAPK) inhibitor U0126. U 0126 195-200 mitogen activated protein kinase 3 Rattus norvegicus 179-183 28476501-12 2017 U0126, a specific inhibitor for ERK-1/2, attenuated the NE-induced proliferation of PASMCs under normoxia and hypoxia. U 0126 0-5 mitogen activated protein kinase 3 Rattus norvegicus 32-39 28646880-10 2017 The inhibitors of Trk receptor (K252a), MEK/ERK1/2 (U0126 and PD98059) and PI3K/AKT (LY294002) attenuated the neuritogenic activity of both NGF and 6-shogaol, respectively. U 0126 52-57 mitogen activated protein kinase 3 Rattus norvegicus 44-50 28587345-6 2017 However, the inhibitory effects were reversed with the addition of U0126, suggesting that the ERK1/2-mediated pathway may be the underlying mechanism responsible for palmitoleate-induced downregulation of insulin mRNA. U 0126 67-72 mitogen activated protein kinase 3 Rattus norvegicus 94-100 28442634-4 2017 Administration of U0126, which is a selective inhibitor of the ERK1/2 pathway, improved renal function, decreased urine microalbumin and inhibited activation of renal interstitial fibroblasts as well as accumulation of extracellular proteins. U 0126 18-23 mitogen activated protein kinase 3 Rattus norvegicus 63-69 28385499-6 2017 Pretreatment with p38 inhibitor (SB202190) and ERK1/2 inhibitor (U0126) attenuated the induction of CYP2E1 mRNA and protein levels by ethanol; however, no change was observed with JNK inhibitor pretreatment. U 0126 65-70 mitogen activated protein kinase 3 Rattus norvegicus 47-53 28101000-5 2016 Moreover, pretreatment of astrocytes with SB202190 (inhibitor of p38 MAPK), U0126 (inhibitor of ERK1/2) or SP600125 (inhibitor of JNK1/2) could suppress the upregulated expression of p-p38, p-ERK1/2, and p-JNK1/2. U 0126 76-81 mitogen activated protein kinase 3 Rattus norvegicus 96-102 28377346-9 2017 The specific inhibitors of ERK signal pathway (U0126) and JNK signal pathway (SP600125) significantly decreased the percentage of BrdU+ cells in RSC96-CM-induced OPCs (P<0.01). U 0126 47-52 mitogen activated protein kinase 3 Rattus norvegicus 27-30 29926606-7 2017 The ERK1/2 pathway activator Staurosporine aglycone reduces the mRNA and protein expression of CLCA2 in rats PASMCs and the ERK1/2 pathway inhibitor U0126 induces the upregulation of the mRNA and protein expressiosn of CLCA2 in rats PASMCs. U 0126 149-154 mitogen activated protein kinase 3 Rattus norvegicus 4-10 29926606-7 2017 The ERK1/2 pathway activator Staurosporine aglycone reduces the mRNA and protein expression of CLCA2 in rats PASMCs and the ERK1/2 pathway inhibitor U0126 induces the upregulation of the mRNA and protein expressiosn of CLCA2 in rats PASMCs. U 0126 149-154 mitogen activated protein kinase 3 Rattus norvegicus 124-130 28374767-7 2017 GPR91 siRNA transduction and the ERK1/2 inhibitor U0126 inhibited the increases in C/EBP beta, C/EBP delta, c-Fos and HIF-1alpha. U 0126 50-55 mitogen activated protein kinase 3 Rattus norvegicus 33-39 27865869-2 2017 U0126, a p-ERK1/2 inhibitor, was injected intracisternally before UAC implant. U 0126 0-5 mitogen activated protein kinase 3 Rattus norvegicus 11-17 27865869-11 2017 Pretreatment with U0126 prevented the upregulation of both p-ERK1/2 and p-p38. U 0126 18-23 mitogen activated protein kinase 3 Rattus norvegicus 61-67 28101000-5 2016 Moreover, pretreatment of astrocytes with SB202190 (inhibitor of p38 MAPK), U0126 (inhibitor of ERK1/2) or SP600125 (inhibitor of JNK1/2) could suppress the upregulated expression of p-p38, p-ERK1/2, and p-JNK1/2. U 0126 76-81 mitogen activated protein kinase 3 Rattus norvegicus 192-198 28011945-12 2016 Inhibition of ERK1/2 by 10 muM U0126 attenuated OXA-stimulated INS-1E cell proliferation. U 0126 31-36 mitogen activated protein kinase 3 Rattus norvegicus 14-20 27768739-8 2016 Inhibition of either GSK-3beta (with SB216763) or ERK1/2 (with U0126) abolished RLIPC-induced antiarrhythmic activity and GSK-3beta Ser9 and ERK1/2 phosphorylation, leaving GSK-3beta Tyr216 phosphorylation unchanged. U 0126 63-68 mitogen activated protein kinase 3 Rattus norvegicus 50-56 27592458-11 2016 Blockage of the ERK1/2 signaling pathway and NF-kappaB using the MEK1/2 inhibitor (PD98059 and U0126) or IkappaB kinase inhibitor (wedelolactone) significantly abolished Hcy-induced up-regulation of ETB receptor. U 0126 95-100 mitogen activated protein kinase 3 Rattus norvegicus 16-22 27212444-14 2016 By using U0126 could inhibit the phosphorylated ERK1/2 protein but not MEK1/2. U 0126 9-14 mitogen activated protein kinase 3 Rattus norvegicus 48-54 27588145-10 2016 In addition, daphnetin induced the expression of HSP70 in a dose- and time-dependent manner, and daphnetin-induced HSP70 expression was reduced by extracellular signal-regulated kinase (ERK) 1/2 inhibitor U0126 in PC12 cells. U 0126 205-210 mitogen activated protein kinase 3 Rattus norvegicus 147-194 29786234-11 2016 When compared with HI+Rg1 group, the expressions of p-Erk1/2 and HIF-1alpha proteins in HI+Rg1+U0126 group were significantly decreased (P<0.05), while expression of CC3 protein was significantly increased at 4 and 24 hours (P<0.05). U 0126 95-100 mitogen activated protein kinase 3 Rattus norvegicus 54-60 27138645-14 2016 These effects were suppressed by the phosphatidylinositol 3"-kinase (PI3K) inhibitor LY294002 and the extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor U0126. U 0126 163-168 mitogen activated protein kinase 3 Rattus norvegicus 102-143 27138645-14 2016 These effects were suppressed by the phosphatidylinositol 3"-kinase (PI3K) inhibitor LY294002 and the extracellular signal-regulated kinase 1/2 (ERK1/2) inhibitor U0126. U 0126 163-168 mitogen activated protein kinase 3 Rattus norvegicus 145-151 27143440-6 2016 The neuroprotective effects of Res were suppressed by pretreatment with MK801, an NMDA receptor blocker, or U0126, an extracellular signal regulated kinase 1/2 (ERK1/2) kinase inhibitor. U 0126 108-113 mitogen activated protein kinase 3 Rattus norvegicus 118-159 27168176-11 2016 The altered BCRP expression and function by ammonia and H2 O2 were restored by ROS scavenger N-acetylcysteine and ERK1/2 inhibitor U0126. U 0126 131-136 mitogen activated protein kinase 3 Rattus norvegicus 114-120 27143440-6 2016 The neuroprotective effects of Res were suppressed by pretreatment with MK801, an NMDA receptor blocker, or U0126, an extracellular signal regulated kinase 1/2 (ERK1/2) kinase inhibitor. U 0126 108-113 mitogen activated protein kinase 3 Rattus norvegicus 161-167 27091895-9 2016 In addition, the requirement of the MEK1/2-ERK1/2 signaling for RGS12-mediated cardiac hypertrophy was confirmed in rescue experiments using the MEK1/2-specific inhibitor U0126. U 0126 171-176 mitogen activated protein kinase 3 Rattus norvegicus 43-49 26363191-4 2016 This ERK1/2 and JNK1/2 phosphorylation was also inhibited by ERK1/2 (U0126) and JNK1/2 (SP600125) inhibitors, respectively, but sustained ERK1/2 phosphorylation was not affected by JNK1/2 phosphorylation. U 0126 69-74 mitogen activated protein kinase 3 Rattus norvegicus 5-11 26825317-8 2016 Erk1/2 activation as well as the phosphorylation of the linker region of Smad2 and MMT could be blocked by the MEK inhibitor, U0126, suggesting that such activation may be a potential pharmaceutical target to prevent MMT. U 0126 126-131 mitogen activated protein kinase 3 Rattus norvegicus 0-6 27016422-8 2016 Blocking PI-3K through wortmannin or ERK1/2 through U0126 attenuated argon-mediated neuroprotection.These data provide a new molecular mechanism for the potential application of Argon as a neuroprotectant in HIE. U 0126 52-57 mitogen activated protein kinase 3 Rattus norvegicus 37-43 26786718-11 2016 ICI 182780, U0126 (an ERK1/2 inhibitor) and SP600125 (a JNK inhibitor) prevented the increases in arterial relaxation and eNOS levels. U 0126 12-17 mitogen activated protein kinase 3 Rattus norvegicus 22-28 26363191-4 2016 This ERK1/2 and JNK1/2 phosphorylation was also inhibited by ERK1/2 (U0126) and JNK1/2 (SP600125) inhibitors, respectively, but sustained ERK1/2 phosphorylation was not affected by JNK1/2 phosphorylation. U 0126 69-74 mitogen activated protein kinase 3 Rattus norvegicus 61-67 26363191-4 2016 This ERK1/2 and JNK1/2 phosphorylation was also inhibited by ERK1/2 (U0126) and JNK1/2 (SP600125) inhibitors, respectively, but sustained ERK1/2 phosphorylation was not affected by JNK1/2 phosphorylation. U 0126 69-74 mitogen activated protein kinase 3 Rattus norvegicus 61-67 26424114-6 2015 The inhibition of MEK/ERK1/2 or PI3K/AKT activity by U0126 or wortmannin, but not the inhibition of phospholipase Cgamma by U73122, prevented FGF9-induced gamma-GCS and HO-1 upregulation, changes in cellular redox status, and neuroprotection against MPP(+) toxicity in primary cortical and dopaminergic neurons. U 0126 53-58 mitogen activated protein kinase 3 Rattus norvegicus 22-28 26636577-6 2015 A decrease in infarct size was observed in an in vivo model of myocardial I/R injury in HCQ treated animals and furthermore this protection was blocked in the presence of the ERK1/2 inhibitor U0126. U 0126 192-197 mitogen activated protein kinase 3 Rattus norvegicus 175-181 26621121-9 2016 We also found that the neuroprotective role of AMN082 was completely reversed by ERK1/2 inhibitor 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene (U0126). U 0126 98-157 mitogen activated protein kinase 3 Rattus norvegicus 81-87 26621121-9 2016 We also found that the neuroprotective role of AMN082 was completely reversed by ERK1/2 inhibitor 1,4-diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene (U0126). U 0126 159-164 mitogen activated protein kinase 3 Rattus norvegicus 81-87 26507774-10 2016 Both a ERK1/2 inhibitor (U0126) and ERK2 siRNA, but not ERK1 siRNA, abolished the protective effect of ATRA against doxorubicin-induced toxicity in H9c2 cells. U 0126 25-30 mitogen activated protein kinase 3 Rattus norvegicus 7-13 26507774-10 2016 Both a ERK1/2 inhibitor (U0126) and ERK2 siRNA, but not ERK1 siRNA, abolished the protective effect of ATRA against doxorubicin-induced toxicity in H9c2 cells. U 0126 25-30 mitogen activated protein kinase 3 Rattus norvegicus 7-11 26075533-9 2015 Treatment with ERK1/2 inhibitors (PD98059 and U0126) abolished the antagonistic effect of TGF-beta1 on TNF-alpha mediated catabolic responses. U 0126 46-51 mitogen activated protein kinase 3 Rattus norvegicus 15-21 26065826-9 2015 The MAPK inhibitors PD98059 (MEK1/2), U0126 (MEK1/2) and SB203580 (P38) prevented but did not reverse paclitaxel-induced behavioral hypersensitivity. U 0126 38-43 mitogen activated protein kinase 3 Rattus norvegicus 4-8 26392309-5 2015 U0126, a specific inhibitor of ERK1/2 pathway was employed to block the ERK1/2 signaling pathway. U 0126 0-5 mitogen activated protein kinase 3 Rattus norvegicus 31-37 26392309-5 2015 U0126, a specific inhibitor of ERK1/2 pathway was employed to block the ERK1/2 signaling pathway. U 0126 0-5 mitogen activated protein kinase 3 Rattus norvegicus 72-78 26392309-6 2015 Western blotting analysis showed that alcohol significantly enhanced the levels of phosphorylated ERK1/2 and induced hyperacetylation of histone3, which were both effectively prevented with U0126. U 0126 190-195 mitogen activated protein kinase 3 Rattus norvegicus 98-104